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ABSTRACT 
 With the development of Highly Active Anti-Retroviral Therapy (HAART), 
Human Immunodeficiency Virus (HIV) infection has evolved from a fatal disease 
to a chronic condition with increased risk for non-infectious comorbidities, 
including reduced bone density. Bone density is maintained through the coupled 
activities of osteoblast matrix deposition and osteoclast resorption; while 
uncoupling this process can result in bone loss and increased fracture risk. CD4+ 
T cells are critical in regulating the activity of these cells.  Relevant to this thesis, 
studies have shown that HAART treated patients experience higher levels of 
immune activation; possibly contributing to the observed bone loss. If 
osteoimmune dysregulation does occur, there is a need to develop therapeutics 
that target this process, especially in the context of HIV infection.  
To evaluate osteoblast differentiation, we developed a high-throughput 
screening method to identify osteo-regulatory compounds. By screening over 
5,000 compounds, we identified 18 that robustly induced osteoblast 
differentiation, using a mouse mesenchymal stem cell. We validated two of these 
compounds, rapamycin and FK-506, which are known immunosuppressants. 
	  	   x 
Secondly, we addressed the role of activated CD4+T cells and HIV-infected T 
cells in osteogenesis.  We found that supernatants from activated T cells potently 
inhibit osteoblast differentiation.  However, when osteoblasts were co-cultured 
with HIV-infected T cells, differentiation was inhibited regardless of activation 
status, suggesting intrinsic differences between HIV infected and uninfected T 
cells.  Finally, to prevent the inhibition of osteogenesis by activated T cells, we 
evaluated rapamycin, our pro-osteogenic and T cell activation antagonist, as well 
as the novel compound JQ1, an inflammatory inhibitor that targets bromodomain-
containing proteins.  Both rapamycin and JQ1 efficiently blocked the cytotoxic 
effects of supernatants from non-infected activated T cells on osteoblasts, 
whereas only rapamycin prevented inhibition in the co-culture model.  In contrast, 
neither rapamycin nor JQ1 were able to prevent inhibition by HIV infected, 
activated T cells.  This suggests that HIV exacerbates the negative effects of T 
cell activation on osteoblastogenesis.  These data support a mechanism for HIV 
infection and T cell activation mediating bone loss. 
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Chapter 1: Introduction to Bone Homeostasis and the Human 
Immunodeficiency Virus 
 
1.1 Significance 
 
At the end of 2012, approximately 35.3 million people were living with Human 
Immunodeficiency Virus (HIV) and 9.7 million of them were receiving anti-
retroviral therapy (ART) (World Health Organization).  Due to the development of 
ART and highly active ART (HAART), HIV has transitioned from a deadly disease 
to a manageable yet chronic condition for those that have access to treatment.  
Many of these patients are in developed countries, including the United States, 
where over 1.1 million people are infected (Centers for Disease Control).  
Recently it has been stated that chronically infected HIV patients experience non-
infectious co-morbidities often associated with aging, including cardiovascular 
disease, diabetes, and frailty due to muscle and bone loss [1-4].  This 
dissertation will address the observation that individuals infected with HIV 
experience a higher incidence of osteoporosis and osteopenia compared to 
uninfected age-matched individuals [5-10].  The mechanisms involved in this 
process are complicated and mainly unidentified.  Several groups report that 
HIV-associated bone loss is due to the treatment regimen, specifically protease 
inhibitors [7]; however, many groups have seen the loss of bone density 
irrespective of treatment and therefore it may be due to an overall systemic 
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change caused by the infection [6, 8].  Determining the mechanisms involved in 
the development of osteoporosis would open new avenues for novel targets and 
therapeutic strategies, therefore improving quality of life.  Many clinical 
populations experience bone loss, ranging from postmenopausal women to those 
with autoimmune disorders, where the causation and pathways involved for each 
type of associated bone loss are disease specific.  Further understanding how 
chronic HIV-infection enhances the rate of bone loss will allow for the 
improvement of disease-specific treatment. 
 
1.2 Overview of HIV 
 
The Human Immunodeficiency Virus (HIV) has been an extremely important 
focus of research over the last 30 years.  In 1981, the Centers for Disease 
Control (CDC) noticed an outbreak of opportunistic infections among injection 
drug users and homosexual men.  These included pneumonia caused by 
pneumocystis carinii and a rare form of skin cancer called Kaposi’s sarcoma, 
diseases that are often associated with an impaired immune system.  The CDC 
originally named this condition the “4H disease” because it affected 
homosexuals, Haitians, hemophiliacs and heroin users [11-16].  In September 
1982, the CDC began referring to this disease as Acquired Immune Deficiency 
Syndrome (AIDS) after realizing its impact among many different communities. In 
1983, two different groups isolated a novel virus from AIDS patients.  Gallo’s 
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group discovered that the virus was similar to human T-lymphotropic viruses 
(HTLV) and therefore named it HTLV-III, but Montagnier’s group stated that the 
core proteins of the virus were different from HTLV and therefore named their 
virus lymphadenopathy-associated virus (LAV) [17-19].  Since these viruses were 
the same, in 1986, LAV and HTLV-III were renamed HIV.   
 
1.2.1 HIV Infection and Life Cycle 
Determining the mechanisms involved in HIV infection and replication has been 
essential for developing therapeutics and understanding systemic changes due 
to infection.  HIV is transmitted through the transfer of bodily fluids, including 
blood, semen, vaginal fluid and breast milk [20].  The major mode of transmission 
is through sexual intercourse. Once the virus is able to enter the body, it targets 
the immune system, specifically CD4+ T cells and macrophages.   
 
HIV is a member of the lentivirus genus, part of the retroviridae family.  The virus 
contains two positive-sense single stranded RNA copies that code for the nine 
essential genes.  These genes are: gag, pol, env, tat, rev, nef, vif, vpr and vpu. 
Gag, pol and env contain the information needed to translate the structural 
proteins.  The six remaining genes encode information for the regulatory and 
accessory proteins essential for guiding replication and infection.  The viral RNA 
is enclosed by a capsid (CA) that is composed of the p24 protein, encoded by the 
gag gene.  Within the capsid, the viral RNA is tightly bound with proteins 
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necessary for virion formation, including enzymes reverse transcriptase and 
integrase, both encoded by the pol gene.  A matrix (MA), also encoded by gag, 
surrounds the capsid.  The envelope is formed when the virion buds from the 
host cell and therefore takes some of the host cell membrane with it.  The env 
gene encodes the envelope proteins gp120 and gp41, critical for infecting 
another cell [21-24].  Gp120 binds to the CD4 molecule on the host cell and gp41 
binds to the chemokine co-receptor, CCR5 (C-C motif) or CXCR4 (C-X-C motif).   
Mutations in gp120 and gp41 occur frequently and determine the tropism of the 
virus. There are three different tropisms of the virus depending on which co-
receptor it utilizes.  R5 viruses prefer to infect macrophages because they 
express the CCR5 chemokine whereas X4 viruses prefer to infect CD4+ T cells 
since they express the CXCR4 chemokine [25-27].  Dual tropic viruses also exist 
and can bind to both co-receptors. When the virus binds to the host cell via its 
envelope proteins, it fuses with the cell.  Once bound, the virus’ RNA along with 
the reverse transcriptase and integrase enzymes enter the cell.  The reverse 
transcriptase converts the single-stranded viral RNA into double-stranded viral 
DNA, allowing the integrase enzyme to insert it into the host cell genome.  When 
the viral DNA is integrated, host cell machinery transcribes it into mRNA allowing 
for translation of the viral proteins needed to form a new virion.  After the 
production of viral protein precursors, the HIV protease cleaves them to generate 
the active forms.  Then the new virion buds from the host cell with its membrane 
and goes on to infect another cell [28-30].   
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The pathogenesis of HIV infection is mostly due to the depletion of CD4+ T cells.  
The mechanism by which HIV kills CD4+ T cells is not completely understood but 
the key mechanism proposed is apoptosis. The HIV-associated proteins Tat and 
gp120 can induce apoptosis along with Fas signaling, promoted by HIV binding 
to the CD4 molecule [31].  However, a recent study found that the main 
contributor of CD4+ T cell depletion is pyroptosis, where HIV infection induces an 
inflammatory response causing surrounding CD4+ T cells to die via a caspase-1 
mechanism [32]. During acute infection, viral levels are high and CD4+ T cell 
counts drastically drop, but many infected individuals remain asymptomatic at 
this point.  After acute infection there is often a period of clinical latency where 
viral levels are low and CD4+ T cell levels increase.  This latency can last from 
months to years.  Eventually, the virus will increase replication and CD4+ T cells 
drop to dangerous levels, making an individual susceptible to opportunistic 
infections.  This is where AIDS symptoms begin and eventually leads to death 
[33, 34].  The discovery of HIV and its structure and function has led to the 
development of very effective therapeutics. 
 
1.2.2 Treatment of HIV 
Fortunately, once the causative agent of AIDS was discovered to be HIV, 
therapeutics were quickly developed to stop the epidemic.  The first treatments 
developed targeted the reverse transcriptase (RT) enzyme.  Azidothymidine 
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(AZT) was the first FDA approved drug in March 1987 and it acts as a nucleoside 
analog reverse-transcriptase inhibitor (NRTI) [35-37].  Non-nucleoside reverse 
transcriptase inhibitors (NNRTI) were also developed to bind to reverse 
transcriptase and therefore inhibit its catalytic activity. Researchers quickly 
discovered that drugs targeting different steps of the HIV life cycle would be 
necessary to keep viral levels low since the virus could become resistant.  
Protease inhibitors were developed as another class of anti-retroviral therapy; 
they prevent the HIV protease from cleaving protein precursors to produce the 
necessary viral particles, including the proteins encoded by gag and env.   Other 
classes of anti-retrovirals include integrase strand transfer inhibitors, fusion 
inhibitors and entry inhibitors [38-40].   Although these drugs are effective 
individually, they are much more effective when given in combination, therefore, 
multi-combinatorial drugs were developed and are the standard treatment of care 
for individuals infected with HIV.   These drugs have changed HIV infection from 
a fatal disease to a manageable one and infected patients are living longer and 
relatively normal lives when treatment regimens are followed.  However, most of 
the HIV-infected population does not have access to these drugs and therefore 
developing a cure and/or vaccine is critical for public health.  
 
Although most patients in the United States that are infected with HIV are 
treated, it has been found that they are not healthy.  For reasons not fully 
understood, chronically infected treated patients appear to be “aging” at an 
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accelerated rate.  Compared to uninfected age matched controls, treated HIV 
patients experience non-infectious, age-related comorbidities including 
cardiovascular disease, hypertension, diabetes mellitus, bone fractures and renal 
failure [4]. Current efforts aim to unravel the mechanisms involved in these 
accelerated aging phenotypes.  This dissertation focuses on the observation that 
HIV-infected individuals experience lower level of bone density and higher 
incidences of fractures.   
 
1.3 Regulation of Bone Homeostasis 
 
To maintain structure and strength of the skeletal system bones are constantly 
being remodeled [41].  This is an active process and involves two important cell 
types; osteoblasts that deposit new bone matrix and osteoclasts that degrade the 
matrix [42]. It is critical that these two activities are regulated in a balanced 
manner and at a homeostatic level that maintains bone density at healthy levels.  
Otherwise, if osteoclast activity is increased, if osteoblast activity decreased, or if 
both activities diminish below levels of homeostatic maintenance, bone density is 
reduced, leading to osteopenia or osteoporosis, which subsequently results in 
pathological fractures. Loss of bone mass not only has a detrimental impact on 
quality of life, but it is also generates high expenses to the healthcare system and 
decreases productivity.  Further understanding the regulation of bone 
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homeostasis will shed light on mechanisms involved in the development of bone 
loss and therefore expand therapeutic approaches.   
 
1.3.1 Osteoblasts and Bone Matrix Deposition 
Several cell types exist in the skeletal tissue and they arise from pluripotent 
mesenchymal stem cells, capable of differentiating into osteoblasts, myoblasts, 
adipocytes and chondrocytes, conditional on the signaling factors present [43-
46].  The most important function of the osteogenic lineage is to form mineralized 
bone.  This process often begins when there is an upregulation of bone 
morphogenetic proteins (BMPs), the most potent factors that promote osteoblast 
differentiation [47-50].  BMPs belong to the larger transforming growth factor-β 
(TGFβ) superfamily.  Similar to TGFβs, BMPs bind to two types of serine-
theronine receptors, BMP type I and type II receptors (BMPRI and BMPRII) [51, 
52]. BMP will bind to the type II receptor first thereby recruiting the type I receptor 
and activate its phosphorylation function.  This allows the type I receptor to 
phosphorylate its intra cellular mediator Smad.  The specific Smads that respond 
to BMP signaling are Smad-1, Smad-5 and Smad-8.  Phosphorylated Smad-1-, 5 
and -8 recruits the common mediator-Smad, Smad-4.  Together, Smad-1 5 and -
8 along with Smad-4 enter the nucleus and act as a transcription factor to induce 
osteoblast-specific genes (Figure 1 and [50]). As with most signaling cascades, 
they must be regulated to prevent over stimulation and constant signaling. The 
proteins noggin, chordin, gremlin and follistatin can inhibit binding of BMP to its 
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receptor [53-56].  Initiation of this signaling cascade is critical for osteoblast 
differentiation and therefore matrix deposition.  
 
Many genes are transcribed after BMP signaling is initiated. The first gene to be 
induced within the mesenchymal lineage that will commit the stem to the 
osteogenic pathway is a transcription factor termed Runt-related transcription 
factor-2 (Runx2) [57, 58].  Runx2 is a critical regulator of bone development and 
without the expression of this gene mice lack osteoblasts and fail to form bone 
tissue [59, 60]. Downstream of Runx2 is, Osterix (Osx), another transcription 
factor necessary for bone development. The transgenic deletion of Osx also 
results in failure to produce bone [61-63]. As the osteoprogenitor cells continue to 
differentiate, other proteins are induced, including alkaline phosphatase (ALP).  
Alkaline phosphatase is responsible for cleaving phosphate groups to induce a 
high concentration of phosphate at the site of mineral deposition and is essential 
for bone formation.  ALP is a common marker used to identify osteoblastic cells 
[64-71]. Mature osteoblasts release both collagenous and non-collagenous 
components to form the bone matrix.  Synthesis of the bone matrix begins with 
the production and deposition of type I collagen, the most abundant component 
of the bone matrix. The collagen provides a scaffold for the calcium mineral 
hydroxyapatite, along with matrix proteins, including osteocalcin (Ocn) and 
osteopontin (Opn), also known as bone sialoprotein-1 (BSP-1) [70, 72-74]. 
Mature osteoblasts that have released the matrix will either die through apoptosis 
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or terminally differentiate into osteocytes and embed themselves into the bone 
matrix [75, 76].  Understanding the progression of osteoblast differentiation and 
bone matrix formation is critical in determining the mechanisms that regulate 
bone density.   
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Figure 1 
A. 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 1: Osteoblast Differentiation and BMP-2 Signaling 
A). The progression of osteoblast differentiation from mesenchymal stem cell 
(MSC) to osteocyte. B). Signaling pathway induced by BMP-2 binding to its 
receptors BMPR-I and –II. P=phosphate group. 
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1.3.2 Osteoclasts and Bone Matrix Resorption 
Osteoclasts are derived from hematopoietic stem cells, capable of differentiating 
into lymphocytes, erythrocytes, monocytes, eosinophils, neutrophils, 
megakaryoctyes and mast cells [77-79].  In particular osteoclasts belong to the 
myeloid progenitor lineage that gives rise to cells of monocyte lineage.  The 
central mediators that direct osteoclast differentiation from the monocyte 
progenitor are macrophage colony-stimulating factor (M-CSF) and receptor of 
activated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
(RANK).  As differentiation progresses mononuclear cells fuse and become 
multinucleated, which is considered an aspect of their terminal development [80].   
Bone resorption begins with attachment of the osteoclast to the bone surface via 
integrin receptors [81].  Once the osteoclast binds to the bone surface it polarizes 
to have three different membrane domains.  The first membrane, the “sealing 
zone,” creates a tight cell-to-matrix interaction to prevent any external factors 
from interacting [82].  This allows for the formation of the basolateral domain that 
is exposed to the external environment [83-85].  The most important domain is 
termed the ruffled border, containing intracellular acidic vesicles and penetrates 
into the bone matrix [72].  To dissolve the hydroxyapatite, acids such as 
hydrochloric acid are secreted from the intracellular vesicles in the osteoclast 
[86].  Following this, the organic part of the matrix, mostly type I collagen, is 
degraded by proteases and proteolytic enzymes such at matrix 
metalloproteinases (MMPs) [87, 88]. Lysosomal cysteine proteinases, such as 
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cathepsin K, participate in the degradation as well [89].  Byproducts of this 
process are endocytosed to the basolateral membrane where it can be secreted 
into the external environment [84, 90, 91].  In a healthy bone environment, 
resorption of the matrix allows for the deposition of new matrix, to preserve the 
optimal matrix structure and mineral content for optimal biomechanical function 
and bone mineral density.  However, too much resorption can lead to frailty and 
osteoporosis. 
   
1.3.3 Osteoblast-Osteoclast Crosstalk 
It is essential that bone density is neither too high nor too low; therefore, a tight 
regulation exists between osteoblasts and osteoclasts.  The crosstalk between 
these two cells is extremely important.  The two major signaling proteins in this 
communication are Receptor for Activated NFκB Ligand (RANKL) and 
Osteoprotegrin (OPG).  RANKL is secreted primarily by osteoblasts and binds to 
its receptor, RANK, found on osteoclasts [42, 92, 93].  The binding of RANKL to 
RANK initiates osteoclast differentiation and activation through a signaling 
cascade involving Tumor Necrosis Factor Receptor Associated Factor (TRAF-6) 
and NF-κB [94, 95].  RANKL is also bound to osteoblasts and therefore direct 
contact between the osteoclasts and osteoblasts can occur.  The activation cycle 
is further regulated by the decoy receptor osteoprotegrin (OPG).  Osteoblasts 
also release OPG, a protein capable of acting as a decoy receptor for RANKL.  
Consequently, less RANKL is available to bind to RANK and bone matrix 
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deposition levels will be higher than bone resorption levels, giving an overall 
increase in bone density.  The ratio of RANKL/OPG is indicative of the activity of 
the bone.  Higher RANKL indicates more bone resorption, whereas higher OPG 
indicates bone formation.  This ratio is used clinically as a biomarker for the state 
of bone remodeling [96, 97]. Figure 2 summarizes this cross talk. 
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Figure 2 
 
 
Figure 2: Osteoblast-Osteoclast Cross Talk 
Osteoblast differentiation (bottom) and osteoclast differentiation and activity 
(right) are regulated by RANK, RANKL and osteoprotegrin (OPG).  
 
 
 
 
 
 
 
 
Active Osteoclast 
Osteoclast 
Pre-osteoclast 
Bone Matrix Osteoprogenitor Pre-Osteoblast Mature Osteoblast 
RANKL 
OPG 
RANK 
	  	   16 
Another critical player in osteoblast-osteoclast cross talk is transforming growth 
factor-β (TGFβ), the most abundant cytokine in bone [98, 99].  Osteoblasts 
synthesize TGFβ and it associates with a latent TGFβ binding protein (LTBP), 
allowing the complex to bind with matrix proteins [100-103].  When bone is being 
resorbed, latent TGFβ is released from the matrix, where the acids and MMPs 
secreted by osteoclasts can cleave the binding protein, resulting in release of 
active TGFβ [102, 104].  Many studies have shown that TGFβ can inhibit the later 
stages of osteoblast differentiation.  For example, when MC3T3-E1 (mouse 
osteoblast) cells are treated with TGFβ, ALP activity is markedly reduced [105]. 
 
Although there have been many studies on the communication from osteoblasts 
to osteoclasts, fewer studies have focused on osteoclast signaling to osteoblasts.  
One mechanism by which osteoclasts can regulate osteoblast activity is through 
the secretion of sphingosine 1-phosphate (SIP).  SIP binds to its receptor found 
on osteoblasts and induces survival and migration of osteoblasts along with an 
increase in RANKL production [106].  Another mechanism involves ephrin b2, 
membrane-bound on osteoclasts, binding to ephb4 found on osteoblasts.  This 
contact-dependent signaling promotes osteoblast differentiation and bone 
formation [107, 108].  Additionally, one group recently established the role of 
semaphorin 4D, expressed by osteoclasts, in the inhibition of osteoblast 
differentiation.  Semaphorin 4D binds to the Plexin-B1 receptor found on 
osteoblasts, inducing RhoA signaling and consequently blocking insulin-like 
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growth factor-1 (IGF-1), a growth promoting protein [109].  Although the 
communication from osteoclasts to osteoblasts is not as well understood, there is 
evidence that it occurs and therefore should be further studied in the context of 
bone loss. 
 
Deregulation in any of these signaling mechanisms will disrupt the homeostasis 
and alter the bone density to an unhealthy level, resulting in medical conditions 
such as osteoporosis and osteopenia.    
 
1.4 Osteoporosis and Osteopenia 
 
Over 8.9 million fractures occur annually worldwide and around 44 million people 
in the United States experience osteoporosis or low bone density (International 
Osteoporosis Foundation and [110]). With increases in the aging population, by 
2050, the worldwide incidence of hip fractures in men and women is projected to 
increase by 310% and 240% respectively [111].   In 2005, total costs including 
prevalent fractures was more than $19 billion [112]. The cost burden to treat 
osteoporosis is immense and is expected to exceed $240 billion costs by 2045 
[113]. Overall, low bone density is an immense economic burden worldwide and 
preventing this by either lifestyle changes or drug treatment will reduce these 
high costs and improve quality of life. 
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1.4.1 Clinical Definition 
Loss of bone mass is often referred to as osteoporosis and osteopenia.  There 
are distinct ways in which these terms are used for diagnosis.  Bone density is 
typically measured through dual energy X-ray absorptiometry (DEXA) scans.  
Once the bone density has been determined, it is compared to “normal” 
individuals.  A t-score is given based on comparison to a healthy young adult and 
a z-score is given based on comparison to someone of the same age, sex, 
weight and ethnic origin.  Both types of scores represent standard deviations 
above or below the average. If the t-score is above -1 bone density is considered 
normal.  If the t-score ranges between -1 and -2.5, osteopenia is diagnosed.  If 
the t-score is below -2.5, osteoporosis is diagnosed.   If the z-score is less than -
2, bone loss may be due to a disease, such as rheumatoid arthritis, and not be 
age-associated.  These scores help clinicians assess the bone status of 
individuals and diagnose proper therapeutics based on causation.   
 
 
1.4.2 Commonly Effected Populations and Mechanisms 
Osteoporosis and osteopenia can occur in all age groups and both genders.  
However, it is mostly associated with post-menopausal women. This is due to the 
role of estrogen in bone formation and its ability to inhibit bone resorption.  
Interleukin-6 (IL-6) has been found to induce osteoclast activity and therefore 
increase bone resorption; estrogen, however, blocks IL-6 secretion by 
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osteoblasts and immune cells, therefore preventing bone loss.  The reduction in 
estrogen levels after menopause allows for IL-6 production and consequent bone 
loss [114-117].    
 
Osteoporosis and osteopenia are also often seen in patients with autoimmune 
disorders, including the rheumatic conditions systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA), and multiple sclerosis (MS) [118, 119].  Both 
RA and SLE occur in women more often than men but RA is more common 
during middle age whereas SLE is common between the ages of 10 and 50.  
Patients with RA and SLE have higher incidence of fracture and bone loss, most 
likely due to TNFα secreted by active immune cells, further reviewed in section 
1.5 [120-124]. In addition to the rheumatic conditions, MS affects women more 
than men and is most common between the ages of 20 and 40.  MS is caused by 
damage to the myelin sheath therefore exposing nerves to inflammatory proteins 
and osteoporosis is a common secondary condition [125, 126].   Osteoporosis 
and osteopenia are also considered diseases of aging since bone cells, like 
many cells within the body, fail to regenerate as time goes on.   
 
1.4.3 Therapeutic Options for Bone Loss 
The mechanisms by which bone loss occurs are complicated and vary amongst 
population groups.  However, it is almost always through an increase in 
osteoclast activity; therefore, treatment options often target the inhibition of these 
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cells so that bone loss can be stopped.  The first generation of anti-osteoporotic 
agents and those that are most widely prescribed for both men and women are 
bisphosphonates.  Several common ones have the trade names Fosamax, 
Boniva and Actonel.  Their structure mimics pyrophosphate groups that have a 
high affinity for hydroxypatatite crystals, thus impairing the ability of osteoclasts 
to form the ruffled border.  They also decrease osteoclast progenitor 
development and induce apoptosis of osteoclasts [127].   More recently, the 
second generation of compounds has entered into therapeutic use.  The first of 
these that was developed is based on blocking the development of osteoclasts.  
The most prevalent is called Denosumab, trade name Prolia.  This therapeutic is 
a fully human monoclonal antibody designed to inhibit RANKL [128].  Finally the 
first of the anabolic agents to be brought to market was recombinant human 
parathyroid hormone (rhPTH, trade name Forteo), which has been shown to 
promote osteoblast formation [129-131].  Additionally, an exciting experimental 
drug, romosozumab, has recently been reported to induce bone formation.  This 
therapeutic is an antibody that blocks sclerostin, which is produced by 
osteoblasts to naturally inhibit bone growth.  Researchers found an 11.3 percent 
increase in bone density in the spine, a significant increase over current drugs 
[132-134].  Although the drug is experimental at this time and is a few years 
away from being available on the market, it is promising and addresses the 
underscored need of forming new bone.   
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1.5 Osteoimmunology 
 
Another point of regulation that maintains bone homeostasis is the immune 
system.  It is now well understood that the immune system regulates the activity 
of osteoblasts and osteoclasts through secreted proteins and that 
osteoprogenitors influence the differentiation of immune cells, giving rise to a 
new area of study referred to as “osteoimmunology” [135].  Most 
osteoimmunology studies have focused on the role of T cells, as will be 
discussed in this dissertation.   
 
1.5.1 T Cells and Osteoclasts 
Osteoclastic bone resorption is a critical component for bone turnover and thus 
maintains bone density levels.  T cells have indirect and direct effects on the 
activity of osteoclasts.  One of the most important regulators that activated CD4+ 
T cells produce is RANKL, consequently inducing osteoclast differentiation and 
activity [136-138].  The function of RANKL in relation to the immune system was 
originally identified as a modulator of T cell growth and dendritic cell function 
[137].  Afterwards it was reported that activated T cells could have a direct effect 
on osteoclast differentiation through the secretion of RANKL [139].  Another 
important modulator produced by activated T cells is tumor necrosis factor-alpha 
(TNFα), capable of altering bone homeostasis in several different ways.  TNFα 
promotes stromal cells to express RANKL, consequently inducing osteoclast 
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differentiation and activity [140]. Additionally, TNFα directly signals to osteoclasts 
and enhances RANKL to potentiate their differentiation and increase their activity 
[141, 142]. These two mechanisms alone are considered to be critical in the 
development of rheumatoid arthritis [120, 143, 144].  Figure 3 summarizes these 
findings.  
 
Although TNFα is considered the prominent factor involved in osteoclast-T cell 
crosstalk, other mechanisms have been reported. Another signaling pathway by 
which osteoclasts are regulated by T cells involves CD40 ligand (CD40L).  One 
group found that co-culturing RANKL-stimulated monocytes with LPS-activated T 
cells enhanced osteoclastogenesis, which was dependent on CD40 ligand [145]. 
Interestingly, another study showed that CD4+ CD25+ T regulatory cells inhibit 
osteoclastogenesis via IL-4 and TGFβ [146].  Cytotoxic T lymphocyte antigen 4 
(CTLA4), the negative regulatory costimulatory molecule on Tregs, contributes to 
the inhibition of osteoclast differentiation [147]. A supporting in vivo study saw 
that Foxp3, an essential factor for regulatory T cells, transgenic mice have 
increased basal bone density levels and are partially protected against bone loss 
induced by ovariectomy [148, 149].  The crosstalk between activated T cells and 
osteoclasts plays a prominent role in the development of bone loss; however, we 
were interested in the potential role of osteoblast-T cell crosstalk.   
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1.5.2 T Cells and Osteoblasts 
Although there is a known relationship between bone cells and the immune 
system, there has been less focus on the role of the immune system on 
osteoblastogenesis.  However, several studies indicate communication between 
CD4+ T cells and osteoblasts. Some studies suggest that activated T cells 
induce osteoblast differentiation from mesenchymal stem cells. For example, 
mesenchymal stromal cells treated with conditioned media from activated 
primary T cells had increased levels of BMP-2 protein and ALP staining, 
indicative of osteoblast differentiation.  Furthermore, a combination of TNFα, 
TGFβ, interferon gamma (IFNγ) and IL-17 acted similarly as the conditioned 
media [150].  In contrast, most studies have found that activated T cells are 
inhibitory for osteoblast differentiation.  A study in mice found that supernatants 
from primary Th1 cells activated by phorbol myristate acetate (PMA) and 
ionomcyin reduced ALP activity of primary osteoblasts and that this was blocked 
using IFNγ neutralizing antibodies.  Interestingly, this study reported no 
differences in transcription of osteoblast genes after supernatant addition [151].  
Another study looked at the ability of supernatants from T cells activated by PMA 
and ionomycin to induce apoptosis of the human osteosarcoma cell line MG63, a 
model for studying osteoblastogenesis [152].   Lastly, lymphocytes isolated from 
mice spleens and activated with lipopolysaccharide (LPS) reduced ALP activity 
and differentiation specific transcription in osteoblast cultures [153].  Although 
there is some insight into how activated T cells regulate osteoblast differentiation, 
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further studies are required to elucidate this relationship and determine how 
different diseases may exacerbate this communication.  Figure 3 summarizes 
these reports.   
 
Recent studies have also focused on the communication of osteoblast/stromal 
cells to hematopoietic cells.  It has been established that the osteoblast lineage 
supports hematopoiesis in the bone marrow [154, 155]. Two groups reported a 
role for mesenchymal progenitors in the maintenance of hematopoietic stem cells 
through Cxcl12, a chemokine responsible for regulating hematopoietic and 
lymphoid progenitors.  More specifically, CXCL12 produced by mesenchymal 
cells is required for hematopoietic maintenance whereas CXCL12 produced by 
osteoprogenitors and osteoblasts supports B lymphopoiesis [156, 157]. 
Understanding that mesenchymal stem cells and hematopoietic lineage cells 
communicate in both directions is necessary for unraveling disease-specific 
changes in this crosstalk.  Additionally, developing healthy and disease specific 
in vivo model systems is critical for evaluating this osteoblast-T cell crosstalk to 
shed light on novel targets for therapeutics.   
 
Several model systems have been developed to study osteoimmunology, 
however, they do no discern whether the phenotypes observed are due to 
osteoclast activation or osteoblast inhibition.  One interesting study induces a 
fracture in wild-type mice and T-cell receptor (TCR) knockout mice.  Mice lacking 
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TCR recovered better from the fracture, indicating T cells can have inhibitory 
properties [158].  Another group found that a mouse model for type II diabetes 
spontaneously developed osteoporotic features compared to control mice.  They 
saw that the matrix protein osteocalcin and the RANKL decoy receptor OPG 
were significantly decreased and RANKL expression was increased in activated 
CD4+ T cells, and therefore suggested this mouse model be used to study 
osteoporosis in the future studies [138].  One group examined the mechanism of 
osteoblast impairment in ovariectomy-induced osteoporosis and saw that aspirin 
could inhibit T cell activation and therefore prevented induced apoptosis by the 
Fas/Fas ligand pathway of bone marrow mesenchymal stem cells [159].  Another 
group used the mouse model for inflammatory bowel disease (IBD), which 
involves the transfer of CD4+CD45RBHi T cells, to study osteopenia.  The found 
that when the T cells are transferred into immune deficient mice, osteopenia 
develops due to a decrease in osteoblasts and increase in osteoclasts and this 
can be prevented by treatment with osteoprotegrin.  They concluded that 
osteopenia in IBD is due to inflammatory cell infiltration and not by malabsortion 
of calcium [160].  Mouse models of osteoimmunology, such as the ones 
described above, are necessary for understanding the mechanisms involved and 
to develop viable therapeutics.   
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Figure 3 
 
Figure 3: Osteoblast and Osteoclast Differentiation Regulated by Activated 
T Cells 
Osteoclast differentiation and activity (right) is positively regulated by RANKL and 
TNFα released by activated T cells.  Osteoblast differentiation (bottom) is 
negatively regulated by TNFα and IFNγ produced by activated T cells.  
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1.6 Reduced Bone Density and Immune Activation in HIV Infected 
Individuals 
 
While a portion of the HIV-infected population continues to live longer due to 
treatment, scientists and clinicians have become aware of new complications.  
An increase in osteoporosis and osteopenia with higher incidences of fracture is 
one of the prominent non-infectious comorbidities of HIV infected individuals 
when compared to age-matched controls.  Interestingly, decreases in bone 
density are observed in both treated and untreated populations.  Many groups 
have suggested that the treatment is causing bone loss, but since untreated 
groups are also affected, another mechanism is probable.  HIV-infected 
individuals also experience higher levels of immune activation, regardless of 
treatment.  An overactive immune system may be contributing to the non-
infectious comorbidities these patients have, including increased bone loss. 
 
 
1.6.1 Studies Supporting Bone Loss in HIV-Infected Individuals 
Studies focusing on bone loss in the HIV population have evaluated both men 
and women along with varying age and ethnicity groups. One study reported that 
HIV infected postmenopausal Hispanic and African-American women had lower 
bone mineral density (BMD) at the spine, total hip and femoral neck, along with 
higher levels of bone turnover markers compared to HIV uninfected women of 
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the same age and ethnicity. They found no differences in BMD between treated 
and non-treated HIV infected groups [1].  A study focused on aging men saw 
lower BMD at both the femoral neck and lumbar spine in the HIV-infected 
compared to the HIV-uninfected.  They also found no significant differences with 
anti-retroviral treatment [10].  Another study in women reported that BMD was 
reduced at both the lumbar spine and total hip sites in HIV-infected compared 
with the uninfected group.  They also found that osteopenia was prevalent in 
54% of the HIV-infected versus 30% in the uninfected.  Similar to the other 
studies, no differences were found among subjects treated with the various 
classes of anti-retrovirals [5].  Contrary to the above studies, a meta-analytic 
review of the literature from 1966 to 2005 found that ART-exposed and protease 
inhibitor-exposed individuals had a higher prevalence of reduced BMD within the 
HIV-infected population.  Regardless, they found that the prevalence of 
osteoporosis in the HIV-infected group was three times greater compared with 
uninfected controls [7].  These studies exemplify the need to screen for 
osteoporosis and osteopenia in the HIV-infected population.  They also 
demonstrate the underlying question: what are the mechanisms involved in the 
development of HIV-associated bone loss? Identifying the pathways and targets 
that are the same and/or different as age-associated bone loss will contribute to 
the development of therapy and improve quality of life for these patients.   
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1.6.2 Molecular Mechanisms for Bone Loss in HIV Infected Individuals  
Many studies have determined that HIV patients have increased bone loss 
compared to uninfected individuals; however, the mechanisms involved are 
unknown.  Most studies have looked at the role the actual virus may have on 
osteoblasts.  However, this may not be physiologically relevant since treated 
patients have undetectable levels of virus.  Notably, the virus cannot infect 
osteoblasts or osteoclasts and therefore implies that the effect of HIV-infection on 
bone maintenance is likely indirect.  Some studies have suggested that the 
accessory proteins of HIV may play a role.  One study looked at Tat’s role on 
osteoclast differentiation.  They found that exogenously added Tat enhanced 
osteoclast differentiation and induced cathepsin K, an enzyme involved in 
resorption. Therefore, bone loss in HIV patients may be partially due to an 
increase in osteoclast activity due to circulating Tat [161].  The same group also 
found that HIV induced apoptosis of osteoblast cells by upregulating production 
of TNFα via gp120-CXCR4 signaling [162].  A few years later, another group 
contradicted this finding and saw that gp120 induces proliferation, not apoptosis, 
of osteoblasts at physiologic concentrations [163].  Although efforts have been 
made to understand the molecular mechanisms in vitro, the process by which 
HIV-infection induces bone loss is still relatively unknown.   
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1.6.3 Increased Immune Activation in HIV 
Fortunately, for patients with access to treatment, HIV-infection has become 
manageable and many individuals are living relatively normal and healthy lives.  
However, while many patients on ART recover their immune system, a significant 
proportion of treated patients fail to achieve these same levels [164-166].   It has 
been reported that HIV-infected individuals experience chronic immune activation 
and inflammation with or without treatment [167, 168].  Infection with any virus or 
bacteria will typically initiate an immune response, causing a cytokine storm.  
These cytokines include interleukins and TNFα and are released by T cells, B 
cells and monocytic cells [169-172].  Although these cytokines are helpful in 
clearing an infection, overproduction and dysregulation can be detrimental to 
other systems within the body, including bone.  Interestingly, HIV-infection 
evades the immune system while depleting it, but immune activation and 
inflammation persists.  This counterintuitive phenomenon most likely plays an 
important role in the acceleration of age-related comorbidities, including frailty 
due to reduced musculoskeletal function.  If left untreated, HIV will develop into 
AIDS and cause death due to opportunistic infections.  Treatment stops viral 
replication and allows the immune system to recover and increase its T cell 
population to properly respond to other infections, therefore preventing the 
likelihood of death by opportunistic infection.  This resurgence of T cells is 
important for defending the body against infections but many studies have 
indicated the resurgence can cause many other problems.  After treatment, 
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certain infections become worse, a condition termed immune reconstitution 
inflammatory syndrome (IRIS).  It is often associated with tuberculosis co-
infection and can lead to death [173].  Normally, however, treatment leads to an 
overall increase in immune activation since the immune system is being restored 
[174, 175].  Inflammatory cytokines in the blood have been found to predict 
overall mortality in HIV, where higher levels of cytokines, such as IL-6, correlate 
with higher mortality and more cardiovascular events [176, 177]. Although some 
of these patients fail to recover their CD4 T cell count, they sustain high levels of 
inflammation [178].  Since both treated and untreated HIV-infected populations 
experience higher levels of overall immune activation, it is rational to suggest this 
plays an important role in the increase of non-infectious comorbidities such as 
cardiovascular disease, diabetes and frailty due to muscle and bone loss.   
 
1.7 Conclusions of Literature and Overall Hypothesis 
 
Effective anti-retroviral treatment increases the lifespan of the HIV-infected 
population; however, they experience non-infectious comorbidities that are 
associated with aging.  Most notably, reduced bone loss occurs at a higher 
frequency in HIV-infected individuals when compared to age-matched uninfected 
controls.  The mechanisms underlying this phenomenon are not well understood 
as some studies suggest a role for anti-retroviral treatments whereas others 
claim treatment does not correlate with the increased incidence of bone loss. 
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Recent studies link the regulation of bone homeostasis to the immune system, 
where disruption of this crosstalk has a negative impact on overall bone density. 
The main mechanism of action for HIV-infection is the disturbance in the immune 
system, leading to increased immune activation.  This persists even with 
treatment.  Therefore, we focused on studying the role of increased immune 
activation in the development of bone loss observed in HIV-infection.   
 
Bone homeostasis is tightly regulated to maintain healthy levels of bone mineral 
density.  When this homeostasis is disrupted bone loss can occur.  Along with 
the crosstalk between osteoblasts and osteoclasts, regulation occurs within 
immune cells.  Immune activation has been proven to be detrimental to bone 
homeostasis in a variety of diseases, including rheumatoid arthritis and multiple 
myeloma.  It is reasonable to suggest that increased immune activation in HIV-
infected individuals may alter bone homeostasis, contributing to the prevalence 
of bone loss.  Most of the focus in osteoimmunology has been on the result of 
osteoclast differentiation and activity with less interest in the osteoblasts.  Since 
these cells are dependent on each other, osteoblasts are likely to be affected in 
addition to osteoclasts.  Understanding the role of immune activation on 
osteoblast differentiation is critical for minimizing the knowledge gap in the 
development of osteoporosis across many populations.   
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Considering the role of the immune system in regulating bone homeostasis and 
chronic immune activation in HIV-infected individuals, we hypothesized that T 
cell activation inhibits osteoblast differentiation, underlying HIV-mediated 
bone loss, and is attenuated by immunosuppressants. To address this 
hypothesis we developed the following aims:  
 
Aim 1: Develop a high-throughput screen to identify enhancers of BMP-2 
mediated osteoblast differentiation. 
 
Aim 2: Determine the effect of activated T cells on osteoblast differentiation and 
inhibition by immunosuppressants. 
 
Aim 3: Identify differences between activated HIV positive and negative T cells in 
their ability to inhibit osteoblast differentiation and their response to 
immunosuppressants.  
 
Figure 4 summarizes our central hypothesis and aims to address this 
hypothesis. The following chapters address our efforts to develop a high-
throughput screen and investigate the role of T cell activation in 
osteoblastogenesis.   
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Figure 4 
 
 
Figure 4:  Central Hypothesis and Aims 
We hypothesized that T cell activation inhibits osteoblastogenesis, contributing to 
bone loss.  We aimed to conduct a high-throughput screen that would enhance 
osteoblastogenesis (Aim 1).  We wanted to establish a role for T cell activation in 
inhibiting osteoblastogenesis and determine the ability of T cell activation 
antagonists to prevent this (Aim 2).  Furthermore, we wanted to establish how 
HIV infection might disrupt normal T cell activation in the inhibition of 
osteoblastogenesis and the ability of antagonists to inhibit this (Aim 3).  
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Chapter 2: Novel High-Throughput Screen Identifies Immunosuppressors 
as Enhancers of Osteoblast Differentiation 
Parts of this chapter were previously published in Bone, 2012, 50:1294-1303. 
Darcy, A., Meltzer, M., Miller, J., Lee, S., Chappell, S. Ver Donck, K., and 
Montano, M.  Copyright 2012. Elsevier Inc.  
2.1 Rationale  
 
Based on the increased incidence of bone loss in HIV-infected individuals as 
described previously and the overall economic burden of osteoporosis among 
various populations, we sought to develop a novel screening method that could 
identify bone-enhancing compounds, the goal for our Aim 1.  Our overall interests 
lay in perturbing the effect of activated T cells on osteoblast differentiation and 
how to attenuate the inhibitory effects of activated T cells.  Before analyzing the 
role of activated T cells in osteoblastogenesis, we wanted to identify compounds 
that could increase osteoblast differentiation that could be further utilized in our 
osteoblast-T cell crosstalk model.     
 
2.1.1 Bone Loss and Lack of Osteoblast Inducing Compounds 
Loss of bone mass is an increasingly common morbidity in our aging society and 
is associated with an increased risk of fracture and frailty. Alarmingly, there is 
increased prevalence of bone loss and fractures in chronic but treated disorders 
such as long-term HIV-1 infection and diabetes mellitus [9, 179]. Understanding 
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the mechanisms that regulate bone mass and the risk factors for disruption of 
this regulation is a critical challenge for developing new and effective 
therapeutics. Crosstalk between bone forming osteoblasts and bone resorbing 
osteoclasts is essential for maintenance of bone homeostasis [41, 42, 180]. Net 
bone loss can occur if there is a loss in osteoblast activity or if there is an 
increase in osteoclast activity [181, 182]. The therapeutic focus for osteoporosis 
and reduced bone mass has been on blocking osteoclast activity (e.g., antibody 
to RANKL, Denosumab [128]). Although these advances are promising, efforts to 
promote osteoblast activity may also be useful in establishing an arsenal of 
therapeutic options in countering bone loss. Bone matrix is maintained by the 
proliferation and differentiation of osteoprogenitor cells, which will eventually 
guide the production of mineralized bone [76, 183]. Mature osteoblasts produce 
alkaline phosphatase (ALP) that can be measured via cell staining [184]. Our 
goal was to utilize this stain as an indicator of lineage progression and identify 
compounds that could enhance osteoblast differentiation.   
 
2.1.2 Utilizing High-Throughput Screening and Overview of Approach 
High-throughput screens are becoming increasingly more common in their use to 
identify novel compounds as therapeutic due to their automation, speed, and 
ability to analyze large numbers of compounds. A clear advantage of this 
approach is that screening molecule libraries has the capacity to probe cellular 
pathways and thus identify novel modulatory nodes quickly and efficiently. For 
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example, a screen was recently done to identify anti-inflammatory compounds for 
use in cystic fibrosis, a condition partially caused by chronic lung inflammation, 
and several expected and unexpected compounds were identified as inhibitors 
[185]. We adopted a similar approach to identify osteoblast promoting 
compounds using a complex set of chemical libraries, including FDA approved 
libraries to libraries of small molecules with unknown function. To find novel 
drugs that promote osteoblast differentiation, we began with the C2C12 cell line 
that is biased to become muscle but can be induced to differentiate along the 
osteoblast lineage in the presence of BMP-2 [186].  There is essentially no 
background ALP staining during this conversion and only 30-40% of cells will 
convert, allowing us to find drugs that would augment this efficiency and 
therefore potentially enhance osteoblast differentiation of pre-osteoblasts. We 
chose two hits, FK506 and rapamycin, for further study because their effect on 
the BMP-2 pathway was unclear. Both of these immunosuppressive drugs have 
previously been implicated in osteoblastogenesis, however the results have been 
contradictory and the mechanisms of action remain uncertain, allowing us to 
explore and identify novel pathways [187-192].  To further validate our screening 
method, we wanted to inhibit osteoblast differentiation and determine the ability 
of the compounds to attenuate this effect.  Transforming growth factor (TGF)-β1 
is an anti-inflammatory cytokine that can function as both an antagonist [193-195] 
and agonist [74, 196, 197] on bone differentiation, depending on context. We 
therefore utilized TGFβ1 under antagonistic conditions to further explore 
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rapamycin and FK506 activity. 
 
2.2 Results Supporting the Legitimacy of High-Throughput Screening  
 
2.2.1 Our high-throughput screen proved to be an effective method for 
identifying compounds that enhanced osteoblast differentiation 
In the course of the lab’s studies on muscle differentiation using the C2C12 cell 
line, it was observed that there was BMP-2-mediated conversion of C2C12 cells 
to osteoblasts based on ALP staining in approximately 40% of cells.  Therefore, 
we wanted to find compounds that could enhance this efficacy. C2C12 cells were 
plated at 750 cells per well in a 384-well plate and were allowed to adhere for 24 
hours in growth media (GM). The GM was replaced with low serum differentiation 
media (DM) (negative control), DM+BMP-2 (basal control), or DM+BMP-2+small 
molecules. After 72 hours, cells were fixed and stained for alkaline phosphatase 
(ALP) and DAPI for nuclei visualization. We found that the negative control wells 
expressed close to zero ALP, reinforcing the specificity of this assay. Positive 
control wells consistently had ALP expression in 20–30% of the cells. Notably, 
there were several phenotypes observed in the wells containing BMP-
2+compound, including: no obvious effect on conversion, attenuated conversion 
to osteoblasts, morphological changes and enhancement or suppression of 
proliferation of cells. Figure 5 shows the strategy for the high-throughput screen.  
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Figure 5 
 
Figure 5: Protocol for high-throughput screening.  
Overview of C2C12 cells switched to DM media (low serum) and that received 
either no BMP-2 (negative control), BMP-2 only (positive control), or BMP-
2+compound. The level of alkaline phosphatase (ALP) activity measured 
colorimetrically was scored in all wells using three criteria (see materials and 
methods section). Retinoic acid is a known enhancer of osteoblast 
differentiation[198] Compounds that enhanced ALP expression were considered 
for further analysis. Plates were run in duplicate. 
 
Osteoblast)lineage)
Plate C2C12 Mesenchymal progenitor cells in 384-well plate 
Add BMP-2 
Myoblast)lineage)
Switch to Differentiation Media 
Add small molecules 
13-cis Retinoic Acid Positive Control Negative Control 
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We were most interested in those compounds that enhanced osteoblast 
formation beyond BMP-2 alone due to their therapeutic potential to promote bone 
formation. To ensure a robust detection of augmenters (i.e., those compounds 
that promoted osteoblast differentiation), we applied three search strategies (i.e., 
visual inspection, ImageJ analysis and Digilab analysis) to measure the effects of 
added compounds' on ALP expression. Images of wells from the initial screen of 
chemical libraries were processed using three different search strategies to 
ensure reproducibility and reduce false positives. Resultant images were 
analyzed using ImageJ software, Digilab eaZYX Image Analyzer software, and 
systematically scanned by eye.  Analysis using ImageJ software indicated 211 
compounds with ALP expression greater than three standard deviations above 
the average (99%) of positive controls. Additionally, analysis using the eaZYX 
Image Analysis software from Digilab indicated 31 compounds that had ALP 
expression in the 95th percentile above the positive controls. Finally, visual 
inspection by eye revealed 44 compounds that appeared to enhance ALP 
expression above representative positive control wells. If a compound well was 
detected as an augmenter of ALP expression in at least two of the three analysis 
search strategies, the compound was considered for further analysis. Cross 
validation of the results from the three analyses revealed thirty-one compounds 
that appeared in only two out of three searches and eighteen compounds that 
were identified in all three searches. Therefore, using three different methods of 
analysis became the most stringent way to determine the strongest positive hits. 
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We were also interested in the functional class types of compounds represented 
in the top 18 hits and whether they included known and/or novel effectors. 
Therefore, we conducted a literature search on the eighteen compounds that 
were identified in all three analyses and organized them into groups based on 
common features. Of the eighteen compounds, eight were retinoid 
derivatives/analogs (13-cis retinoic acid, bexarotene, TTNPB, etc.), four known 
immunosuppressant drugs (FK-506, mycophenolate mofetil, mycophenolic acid, 
and rapamycin), two prostaglandins (prostaglandin B2 and prostaglandin E1), 
one fatty acid (C2 dihydroceramide), one platelet-activating factor (PAF) receptor 
antagonist (PCA 4248), one anticonvulsant medication (phenytoin), and one 
antimalarial medication (quinine). There were also notable hits among the top 45 
compounds including resveratrol, which has been implicated in pro-osteogenic 
activity [199, 200]. Figure 6 summarizes the analysis and results.   
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Table 1 
 
Table 1: Results from 5 Small Compound Libraries 
Five different chemical libraries were used and the number of compounds in 
each library is indicated in the table. The number of hits per library is broken 
down into “strongest hits” and “potential hits.” Strongest hits were characterized 
as compounds that were positive in all three analyses, whereas potential hits 
were characterized as compounds that were positive in two of the three 
approaches. The BU-CMLD is composed of stereochemically and structurally 
complex chemical libraries (spiroketal, epoxyquinol, oxime, macrodiolide, 
diketopiperazine, cyclic ether). This library uniquely probes three-dimensional 
space by employing stereochemical and positional variation within the molecular 
framework as diversity elements for library design. The NIH and FDA approved 
drug library, and ICCB are comprised of small molecules that are all known 
bioactives. These collections were assembled to affect a wide variety of 
biological pathways. The ChemBridge represent drug-like small molecules, 
rationally selected based on 3D pharmacophore analysis to cover the broadest 
part of biologically relevant pharmacophore diversity space. 
 
Library Name Number of Compounds Strongest Hits Potential Hits
NIH   446   1   6
ICCB   480 13 13
FDA   640   4   3
BUCMLD 1839   0   1
ChemBridge 2000   0   4
Total 5405 18 27
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Figure 6 
 
Figure 6: Venn diagram depiction of the 3 analysis approaches.  
ImageJ analysis was used to find compounds that were three standard 
deviations above the positive controls. 211 compounds were identified with 
ImageJ. Digilab analysis was used to find compounds that were in the 95th 
percentile and 31 compounds were identified under this category. The 
compounds were also analyzed by visual inspection with 44 noted. Of these, 18 
compounds were common to all three analyses. Functional categories of the 18 
compounds are indicated in the inset box. 
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After screening 5405 compounds in duplicate from five different chemical 
libraries, we applied a cutoff filter that revealed 45 compounds with enhanced 
ALP expression. From these 45 hits (18 strongest hits and 27 potential hits, 
Table 1) we decided to further evaluate two unexpected compounds, rapamycin 
and FK-506 (FK-520 was also identified but was not among the top hits), for their 
effect on the pre-osteoblast mouse cell line MC3T3. We chose rapamycin and 
FK-506 to validate our screen because they are not widely recognized as 
osteoblast potentiators and would therefore indicate the effectiveness of the 
screen. Collectively, we found that screening a large number of compounds 
allowed us to identify several expected compounds due to their known roles in 
activating osteoblast differentiation, along with unexpected compound not 
previously reported to have activity on osteoblastogenesis.  
 
2.2.2 Mouse pre-osteoblast cells validated the enhancement of osteoblast 
differentiation by FK-506 and Rapamycin  
To validate our screening assay with functional assays, we utilized an osteoblast 
precursor cell line, MC3T3-E1, with the two compounds rapamycin and FK506. 
These compounds were initially added in with BMP-2, where upon engagement 
with BMPR-I/II, promotes phosphorylation of Smad 1/5/8 (P-Smad 1/5/8) and 
downstream activation of osteoblastogenesis genes such as Runx2 and Osx [42, 
61, 76]. Levels of P-Smad 1/5/8 were used as a marker of osteoblast 
differentiation due to its involvement in BMP-2 signaling.  As shown in Figure 7A, 
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rapamycin was added to MC3T3 cells in addition to BMP-2 and protein was 
collected 5 and 10 min after stimulation. P-Smad 1/5/8 levels were measured via 
western blot and compared to total Smad 1/5/8 levels. Rapamycin significantly 
increased phosphorylation (lanes 3 and 6). The same experiment was carried out 
with FK-506 and an increase in phosphorylation was also observed (Figure 7B, 
lanes 3 and 6), indicating that both immunosuppressants increase signaling of 
BMP-2.  
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Figure 7 
A. 
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B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Rapamycin and FK-506 increase BMP-2 induced phosphorylation 
of Smad 1/5/8. MC3T3 pre-osteoblast cells were plated at a density of 8x105 
cells per 9.6 cm2 well. 100ng/mL BMP-2 was added to differentiate the cells with 
A). 1µM rapamycin or B). 1µM FK-506. Total protein was collected at 5 and 10 
minutes and analyzed by western blot with antibodies to P-Smad 1/5/8 and total 
Smad 1/5/8. Graphs are shown as a ratio of phosphorylated and total Smad 1/5/8 
and compared to untreated samples. Shown are representative results of at least 
three independent experiments. (* indicates p-value=0.001, students-t test). 
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To determine whether osteoblast specific genes were increased with rapamycin 
and FK-506 addition, the compounds were added to the cells with BMP-2 and 
RNA was collected 6 hours and 24 hours after stimulation.  Runx-2 and Osx 
transcripts, markers of osteoblast differentiation, were analyzed using 
quantitative real-time-PCR (qRT-PCR).  Both compounds significantly increased 
Runx2 and Osx transcripts, although Osx had a much more robust change, 
especially after 24 hours (Figure 8). The greater change in Osx is somewhat 
expected since Runx2 levels are tightly regulated and must be shut down at 
certain time points to allow for differentiation to continue [58]. 
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Figure 8 
A. 
 
B.	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Figure 8: Rapamycin and FK-506 increase BMP-2 induced Runx2 and Osx 
transcripts. MC3T3 pre-osteoblast cells were plated at a density of 8x105 cells 
per 9.6 cm2 well. 100 ng/mL BMP-2 was added to differentiate the cells with A). 
1µM rapamycin or B).1 µM FK-506. Cells were harvested at 6 hours and 24 
hours, RNA was purified and target transcripts Runx-2 and Osx were analyzed 
by qRT-PCR. UT = untreated and Stim = stimulated with the indicated 
compound. Values represent fold change compared to untreated samples after 
normalization using the ΔΔCT method. Shown are representative results 
(average of duplicates) of at least three independent experiments. (* indicates p-
value=0.001 for both Runx2 and Osx, students t-test). 
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We were also interested in whether BMP-2 was essential for enhancement of 
osteoblast differentiation by rapamycin and FK-506. To address this, we 
evaluated bone markers in response to rapamycin and FK-506 alone. As shown 
in Figure 9, both FK506 and rapamycin were sufficient to increase P-Smad 1/5/8 
ratios (Figure 9A, lanes 4, 8, 12) and Osx and Runx2 mRNA levels (Figure 9B). 
However, the level of induction was not as dramatic as it was when combined 
with BMP-2 but did reach levels similar to BMP-2 alone.   
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Figure 9 
A.  
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B.  
 
Figure 9: Rapamycin and FK-506 induce osteoblast differentiation 
independently of BMP-2. The same experiments were done as shown in Figs. 3 
and 4, except rapamycin and FK-506 were added to the MC-3T3 cells without 
BMP-2. A). Phosphorylation of Smad 1/5/8 was observed at 5, 10 and 30 min 
after stimulation and compared to total Smad 1/5/8 levels via western blot. The 
graph represents the ratio of P-Smad to total Smad and is representative of 3 
independent experiments. B). RNA was collected 24 hours after stimulation and 
analyzed by qRT-PCR for Runx2 and Osx levels. The values for the graph were 
determine by ΔΔCT and compared to the untreated sample and were normalized 
to 18S. This was representative of three independent experiments (* indicates p-
value=0.02 for both Runx2 and Osx, students t-test). 
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Since the compounds had an effect on early differentiation capability, we wanted 
to assess their influence on late differentiation. Osteocalcin (Ocn) is an 
osteoblast-specific marker of late differentiation and is often observed at later 
time points, e.g., 14 days and later. Similar to previous experiments, FK-506 and 
rapamycin were added to the cells with or without BMP-2, with new media and 
compounds replaced every two days. We observed that Ocn transcripts were 
significantly increased only when FK-506 was present, independently of BMP-2 
(Figure 10A). In addition to analyzing Ocn transcripts, Alizarin-Red staining, 
which binds to calcium deposits, was conducted to measure mineralization. 
Staining was done after 21 days and images were captured demonstrating an 
increase in the level of mineralization with FK-506 treatment, with or without 
BMP-2 (Figure 10B and C). 
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Figure 10  
A.  
 
B. 
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C. 
 
Figure 10: FK-506 induces late differentiation markers.  
MC-3T3 cells were plated at a density of 8x105 cells per 9.6 cm2 well and treated 
with 100 ng/mL FK-506 in the presence or absence of 100 ng/mL BMP-2. A). 
Media were replaced with fresh compound stimulation every two days and then 
RNA was collected and purified for qRT-PCR of Ocn mRNA transcripts on day 
14. Values in the graph represent fold change compared to untreated samples 
after normalization using the ΔΔCT method. Shown are representative results 
(average of duplicates) of at least three independent experiments. (* indicates p-
value=0.001). B). Media were replaced with fresh compound simulation every 
two days and then stained on day 21 with Alizarin-Red. Pictures are 
representative of three independent experiments. C). Quantification was done 
using ImageJ (* indicates p-values=0.02, students t-test). 
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2.2.3 Rapamycin prevents inhibition of osteoblast differentiation mediated 
by TGFβ  
After establishing that FK-506 and rapamycin could enhance BMP-2 induced 
osteoblast differentiation, we were interested in exploring whether rapamycin and 
FK506 were capable of attenuating TGFβ1 mediated decline in 
osteoblastogenesis, an antagonistic effect that has been well documented [182, 
194, 201]. When TGFβ1 was added to MC3T3 cells, it reduced basal levels of 
Runx2 and Osx mRNA as well as prevented the induction of these transcripts by 
BMP-2, as expected (Figure 11). However, only when rapamycin was added 
with BMP-2 to cells after 24 hours of TGFβ1 pre-treatment, the ability of TGFβ1 
to inhibit upregulation of these markers was attenuated (Figure 11A). These data 
suggest that rapamycin, but not FK-506, interferes with the TGFβ1 pathway, 
consistent with their different mechanisms of action.  
 
We also wanted to determine whether Smad-7 is a target of rapamycin.  Smad-7 
is upregulated in osteoblast differentiation [202] and suppresses Smad-2/3, 
which is downstream of TGFβ1 [203].  As shown in Figure 11B, rapamycin 
augmented Smad 7 expression in the context of BMP-2 and TGFβ1; whereas 
TGFβ1 had no apparent effect on Smad-7 levels. Because BMP-2 alone induces 
Smad-7, BMP-2 signaling may involve activation of protective factors that 
negatively regulate Smad-2/3, further ensuring expression of bone markers.  
Collectively, these data suggest that while both immunosuppressants are 
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capable of inducing bone markers, they nevertheless differ in mechanism of 
activity. 
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Figure 11 
A. 
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Figure 11: Rapamycin prevents inhibition of osteoblast differentiation by 
TGFβ while increasing induction of Smad 7 transcripts.  
MC3T3 cells were treated with media containing 1 ng/mL of TGFβ1 for 24 hours 
and then the media were replaced with BMP-2 or BMP-2+rapamycin. RNA was 
collected 24 hours after treatment and analyzed by qRT-PCR and the ΔΔCT 
method. A). Values of Runx2 and Osx transcripts are represented as fold change 
compared with untreated samples (* indicates p-value=0.02). B). Values of 
Smad-7 transcripts. Shown are representative results (average of duplicates) of 
at least three independent experiments. (* indicates p-value=0.03, students t-
test). 
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2.3 Conclusions and Discussion of High-Throughput Screen Results 
 
2.3.1 Summary of Results 
Developing new therapeutics for osteoporosis is critical for a variety of clinical 
populations.  It is important to not only stop the bone loss, but to promote new 
bone growth.  Our novel high-throughput screening approach identified bone-
promoting compounds that induce osteoblastogenesis in vitro. Among the 5405 
compounds, from several chemical libraries that were screened, 45 compounds 
were identified and cross-validated using three different criteria. Two compounds 
were of particular interest to us due to their notable role as immunosuppressive 
drugs since our interests were focused on activated T cells inhibiting osteoblast 
differentiation (i.e., rapamycin and FK506, [204]). Our results support prior 
studies suggesting an osteogenic role for rapamycin and FK506. After we were 
able to validate the use of FK506 and rapamycin in promoting 
osteoblastogenesis, we evaluated the capacity for these compounds to attenuate 
bone growth antagonists. Because TGFβ1 has a prominent role in bone loss and 
has been previously shown to inhibit osteoblastogenesis, this antagonist was 
chosen [104, 194, 205]. Our data support a capacity for rapamycin but not FK-
506 to rescue TGFβ1 mediated inhibition. By studying these compounds in the 
context of antagonist perturbation that share features with common bone disease 
models, we were able to gain further insights into the signaling pathways 
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involved in the inhibition of osteoblast differentiation.  
 
2.3.2 Other Compounds Identified in High-Throughput Screen 
Among the most potent compounds identified in this screen were the retinoids, 
metabolically active forms of Vitamin A. Reports of in vivo experiments clearly 
show enhanced bone healing after injury in mice with increased Vitamin A in their 
diet and those studies have suggested that retinoic acid enhances osteoblast 
differentiation by increasing BMP2 mRNA expression [206]. Notable compounds 
among the strongest hits and potential hits (Table 1) included five commonly 
used immunosuppressant drugs (rapamycin, FK-506, FK-520, mycophenolate 
mofetil and mycophenolic acid) that are reported to function differently but 
ultimately suppress B and/or T cell proliferative responses [207-209]. We also 
identified four different DNA topoisomerase inhibitors as well as two actin 
polymerization inhibitors. Another group of interest that enhanced ALP 
expression were the prostaglandins (prostaglandins B1, E1, E2 and 13,14-
Dihydro-prostaglandin E1). It is interesting to note that our high-throughput 
screen identified different compounds that fell into specific functional classes, 
suggesting common mechanisms of action affecting osteoblast lineage 
progression. An unexpected observation for the majority of compound hits that 
enhanced ALP expression in our screen was their negative effect on cell 
proliferation. A general model for an inverse relationship between proliferation 
and differentiation has been proposed, possibly explaining why our hits would 
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induce differentiation at the same time they prevent proliferation [210].  
 
2.3.3 Rapamycin and FK-506 Reported Effects on Bone 
It has been conveyed that different immunosuppressant regimens used for organ 
transplant have varying effects in post-transplantation bone loss [211, 212]. In 
vitro and in vivo data show conflicting results, possibly due to the wide variation 
of conditions and concentrations of immunosuppressant drugs used [213]. In 
vitro, FK-506 has been reported to enhance osteoblast differentiation at low 
concentrations (10 nM–1 µM) [192]. In contrast, at higher concentrations (>25 
µM), FK-506 inhibits osteoblast differentiation. Interestingly, rat studies have 
suggested that FK-506 treatment decreased bone mineral density whereas 
rapamycin was indicated to be bone sparing [214]. However, one study 
demonstrates that FK-506 increased bone formation in the alveolar bone of rats 
[215]. Recently, several studies have identified novel therapeutic applications for 
rapamycin, making it important to note that currently approved drugs may have 
other useful functions. One study described that rapamycin was able to increase 
longevity in mice [216]; whereas another recent study has shown that rapamycin 
can reverse the phenotype of Hutchinson-Gilford Progeria Syndrome, a rapid 
aging disease, in a cell model [217]. For our screen, the immunosuppressant 
drugs were tested at relatively low doses (i.e. 1 µM).  
 
Although rapamycin and FK-506 share common signaling targets (i.e., Smad-
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1/5/8), they also have compound specific effects. FK-506 is a well-recognized 
calcineurin inhibitor and rapamycin inhibits the mammalian target of rapamycin 
(mTOR). Both compounds become active when bound to FKBP12 and are 
indicated in our graphical model (Figure 12). Calcineurin is a phosphatase that 
acts upon nuclear factor of activated T cells (NFAT) allowing it to translocate into 
the nucleus and act as a transcription factor [218]. Constitutively active NFATc1 
has been shown to inhibit osteoblast differentiation and function [219]. mTOR's 
role in osteoblastogenesis is not as clear but it has been reported to be critical in 
the differentiation of mesenchymal stem cells [187, 189, 220]. Whether 
rapamycin's suppression of mTOR contributes to the rescue from TGFβ1 
suppression will require further study. The capacity for both rapamycin and FK-
506 to enhance osteoblastogenesis independently of BMP-2 may be due to low 
but detectable levels of BMP-2 present in unstimulated cells. A model describing 
the augmentation of BMP-2 consistent with our observations is shown in Figure 
12. In this model, both FK-506 and rapamycin promote phosphorylation of Smad 
1/5/8. This, then, allows for the downstream signaling leading to activation of 
osteoblast specific genes. Either alone or in the presence of exogenous BMP-2, 
these compounds, or more potent derivatives, show promise for promoting 
osteoblast differentiation. Interestingly, only FK-506 was observed to enhance 
late differentiation, indicating that FK-506 and rapamycin signaling are non-
redundant. One possible explanation may be differential effects on Runx2 levels 
during late differentiation, explaining why rapamycin did not enhance Ocn 
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transcription or mineralization. The different activities of rapamycin and FK-506 
are important to establish prior to consideration for novel therapeutic potentials. 
 
2.3.4 Transforming Growth Factor-beta and Bone Loss 
Notably, TGFβ1 can promote osteoblastogenesis, often in the very early stages 
of commitment [221]. In this study, however, we chose to focus on the inhibitory 
role due to previous studies linking increased TGFβ1 levels with decreased bone 
mass [205]. TGFβ1 has been demonstrated to decrease osteoblast differentiation 
[194, 222] and in vivo experiments have shown that blockade of TGFβ1 results in 
increased bone mineral density accompanied by increased osteoblast numbers 
[193]. Elevated TGFβ1 has been implicated in several disease states. For 
example, TGFβ1 is increased in the serum of HIV positive patients compared to 
HIV negative patients. These HIV positive patients also have increased loss of 
bone density compared to their HIV negative age matched controls [6, 223]. 
Although FK-506 and rapamycin both acted to increase osteoblast formation in 
our system, they were not equally efficacious in attenuating TGFβ1 mediated 
decline in osteogenic signaling. Only rapamycin was able to diminish the 
decrease caused by TGFβ1. Figure 12 shows a hypothetical model for TGFβ1 
inhibition and the ability of rapamycin to rescue. Previous studies indicate that 
TGFβ1 can signal through two different pathways; a canonical pathway that 
induces Smad 2/3, which blocks osteogenesis, and a non-canonical pathway that 
induces mTOR, also blocking osteogenesis [224, 225]. Based on the literature, 
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we believe that when rapamycin is introduced to pre-osteoblasts, blockage of 
mTOR leads to downstream effects on the non-canonical TGFβ1 signaling 
pathway. The rapamycin–FKBP12 complex is known to bind mTOR and, thereby, 
block p70s6kinase (p70s6K) activation [226]. Rapamycin has been shown to 
potentiate osteoblast differentiation via a p70s6K dependent manner [227]. It has 
also been proposed that mTOR signaling affects Sp1 transcriptional activity 
[228]. Sp1 has previously been implicated in TGFβ1 signaling [229] and 
overexpression of Sp1 resulted in six-fold increase of basal Smad 7 promoter 
activity [230], indirectly enhancing Smad 7 activity, a TGFβ1 inducible antagonist 
[203, 231]. Therefore, Smad 7 upregulation may assist but is insufficient for 
rapamycin to attenuate TGFβ1 induced repression of osteoblast differentiation, 
since FK-506 also induces Smad-7. FK-506 did not appear to significantly rescue 
TGFβ1 mediated decline in osteoblast differentiation. Further studies are clearly 
needed to dissociate the effects of rapamycin and FK-506 on TGFβ1 signaling.  
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Figure 12 
 
Figure 12: Graphical model of role for rapamycin and FK-506 promoting 
osteoblastogenesis 
In this chapter, we found that rapamycin and FK-506 induce phosphorylation of 
Smad-1,5,8 and consequently induce transcription of runx2 and osx. It is known 
that these compounds bind to FK-506 binding protein-12 (FKB12) but have 
separate mechanisms of action.  Rapamycin inhibits mTOR while FK-506 inhibits 
calcineurin.  We also found that TGFβ inhibits runx2 and osx transcription.  We 
think that rapamycin can prevent TGFβ mediated inhibition by preventing mTOR 
from inhibiting SP-1, an inducer of Smad-7. Smad-7 is an inhibitor of Smad 2/3 
and we found that it increased with rapamycin treatment.     
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2.3.5 Overall Conclusion and Limitations 
Although this high-throughput screen was focused on the identification of bone 
promoting compounds, an added advantage of our high-throughput approach is 
the utility for discovery of novel pathways with desirable outcomes. For example, 
our screen identified a platelet activation factor (PAF) receptor antagonist as a hit 
that increases osteoblast formation. Identifying this hit allows for the further study 
of the role of PAF receptors in the mechanism through which bone is formed. An 
isolated study has reported a potential role of PAF in bone metabolism [232] but 
there has been no follow up on this observation, making the need for pathway 
analysis even more clear. High-throughput screens may also allow for the 
identification of multiple alternatives for use in patient oriented approaches by 
providing multiple alternative pathways that may overcome host specific deficits, 
such as genetic diseases in one pathway. Thus, high throughput screening is a 
powerful technology in translational medical research (i.e., targeted 
therapeutics). The more obvious benefit to high throughput screens is the ability 
to discover new drugs quickly and efficiently. An additional benefit is the ability to 
use the compound hits to explore functional mechanisms. Through these 
benefits, we were able to identify an uncommon role for two common 
immunosuppressants. Further studies will need to be done to understand either 
their true potential, or derivatives thereof, as potential therapeutics in mitigating 
bone loss. 
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Although the high-throughput screen was successful in identifying inducers of 
osteoblast differentiation, limitations of the study exist.  The screen failed to look 
at the effects of the compounds on the C2C12s without BMP-2.  Compounds that 
are capable of inducing osteoblast differentiation without BMP-2 might have been 
stronger hits.  Typically, the goal of a high-throughput screen is to find novel 
compounds that have not previously been described.  Although we chose to 
validate our screen with known inducers of osteoblast differentiation, we did not 
validate unexpected or novel compounds and determine their ability to induce 
differentiation.  Our high-throughput screen would be stronger if we validated an 
unexpected compound and it could be further utilized to screen other 
compounds.  We also only looked at once concentration and did not titrate 
rapamycin or FK-506 to determine an effective dosage.  Doing so would have 
given us more information on their ability to induce osteoblast differentiation.  
Additionally, our methods of analysis were very labor intensive.  It would be 
beneficial to detect positive hits quicker and more efficiently so that it could be 
used to screen and quickly identify novel compounds.  Although there are 
limitations to this study, we were able to develop a novel screen and validate 
some of our findings. 
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2.4 Future Directions for High-Throughput Screen 
 
2.4.1 Validate Remaining Compounds 
We were able to validate two of the 18 compounds that robustly induced 
osteoblast differentiation but validating the remaining 16 would strengthen the 
use of this high-throughput screening method in the future.  If some of the 
compounds could not be validated, it would identify weaknesses in the screen 
that could be improved upon.  Several of the compounds identified are novel and 
could be useful to develop new therapeutics for osteoporosis.  Validating these 
compounds in mouse models would be necessary to consider them for human 
use in the future.   
 
2.4.2 Develop Challenge Screen 
It would also be useful to develop high-throughput screening methods that could 
utilize a disease specific system.  For example, expanding upon our results and 
challenging osteoblasts with an inhibitor such as TGFβ1 and then screening a 
library could identify compounds able to attenuate the inhibition.  This is relevant 
for multiple myeloma, since patients with this disease experience osteoporosis 
and one of the mechanisms reported to be involved is the inhibition of osteoblast 
by TGFβ1 [119, 201]. High-throughput screens are a valuable tool for developing 
new therapeutics for a variety of diseases and addressing uncommonly 
addressed cell types can provide a variety of treatment options.   
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Chapter 3: HIV Infection and Immunosuppressors Alter Inhibition of 
Osteoblast Differentiation via T Cell Activation 
 
3.1 Rationale  
 
In chapter 2, we addressed the underlying need for the development of bone-
enhancing therapeutics.  Interestingly, we found that the immunosuppressants 
rapamycin and FK-506 were capable of inducing osteoblast differentiation.  This 
was relevant for our second and third aims, focused on the role of T cell 
activation in osteoblastogenesis. Our second aim for this dissertation was to 
determine the effect of activated T cells on osteoblast differentiation and 
inhibition by immunosuppressants.  We wanted to establish that activated T cells 
were capable of inhibiting osteoblastogenesis and the effect of T cell activation 
antagonists (i.e. immunosuppressants) on this inhibition of osteoblast 
differentiation.  Our third aim focused on finding differences between activated 
HIV positive and negative T cells in their ability to inhibit osteoblast differentiation 
and respond to immunosuppressants.  Both of these aims are addressed in this 
chapter. 
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3.1.1 Bone Loss in HIV-Infected Individuals and a Role for 
Osteoimmunology 
With the recent development of anti-retroviral therapy, HIV-infection has become 
a manageable yet chronic disease.  This has led to an increased incidence of 
non-infectious comorbidities compared to uninfected age-matched controls [2, 4]. 
This phenomenon is often referred to as “accelerated aging” since these patients 
display conditions associated with old age [2, 233].  Specifically, reduced bone 
density, leading to frailty and susceptibility to fractures, is increased in HIV 
infected individuals, yet the mechanisms remain unclear [9].  Interestingly, 
treated patients also have an increase in overall immune activation, possibly 
contributing to the increased incidence of non-infectious comorbidities observed 
in these patients [174, 175, 234, 235].  It is well established that the immune 
system influences the maintenance of bone homeostasis and therefore this 
increase in immune activation likely contributes to the development of HIV-
associated bone loss.  
 
Although we are focused on understanding the contribution of immune activation 
to bone loss in HIV-infected individuals, our findings will add to the overall study 
of osteoimmunology.  Osteoimmunology focuses on understanding the 
relationship between the immune system and the cells involved in maintaining 
bone density, specifically osteoblasts and osteoclasts. Studies have found that 
activated CD4+T cells secrete RANKL and TNFα, consequently inducing 
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osteoclast differentiation and activity [135, 143, 236-238].  Autoimmune disorders 
such as rheumatoid arthritis and multiple myeloma result in bone loss and it is 
thought to partially be due to overactive T cells [119, 239].  In contrast, few 
studies have been done to understand the role of osteoblasts under conditions 
where the immune system is activated and the influence these cells may have 
towards bone loss in disease states.  Therefore, we wanted to acknowledge the 
underscored need to understand the role of activated T cells in 
osteoblastogenesis and how this may differ in an HIV-infection model.  Although 
our focus is bone loss in HIV infection, the knowledge gained from this 
dissertation is applicable to a variety of disease states beyond HIV infection.   
 
3.1.2 T Cell Activation and Overview of Approach 
The goal herein was to investigate an effect of activated CD4+T cells on 
osteoblasts and whether that could be attenuated using antagonists of T cell 
activation.  It was also of interest to determine if HIV infection status would 
exacerbate this inhibition or be unresponsive to antagonists.  Activation of 
CD4+T cells is typically induced by the binding of the T cell receptor (TCR) and 
CD3 molecule to a peptide on the antigen-presenting cell (APC). The APC also 
has a receptor for the CD28 molecule present on CD4+ T cells.  When both the 
TCR/CD3 and CD28 molecules are stimulated, they activate NFAT and NF-κB 
signaling respectively [240].  Calcium levels increase when T cells become 
activated and therefore the calcium channel is stimulated, consequently inducing 
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NFAT as well [241].  These then act as transcription factors to activate 
interleukin-2 (IL-2) along with other activation proteins, such as TNFα, CD40LG 
and RANKL.  This is summarized in Figure 13A.   
 
To address the role of CD4+T cell activation in osteoblast differentiation and any 
further effects due to HIV infection such as further inhibition of 
osteoblastogenesis, we utilized primary human CD4+ T cells along with Jurkats 
and J-Lats, commonly used human T cell lines.  J-Lat cells are a line of Jurkat 
cells that have been virally infected with the HIV genome and therefore 
constitutively express HIV. However, they do not produce infectious particles 
since env and nef were deleted from the genome sequence.  These cells are 
often used as a model for HIV latency to test the ability of small molecules to 
activate HIV transcription [242]. See Figure 13B for the HIV gene expressed in 
J-Lats.  To attenuate T cell activation, we used a known immunosuppressant and 
pro-osteogenic compound found from our high-throughput screen, rapamycin, 
along with the novel compound JQ1, an inhibitor of bromodomain-containing 
proteins. JQ1 has been used as an anti-cancer drug and recently has been found 
it to be effective in activating latent HIV.  JQ1 has been reported to have anti-
inflammatory properties in macrophages [243] and therefore we wanted to 
investigate its activity on T cell activation in HIV-infected and uninfected cells 
since it hasn’t been reported.  Although it is known that rapamycin can inhibit T 
cell activation, we wanted to see if it could attenuate inhibition of osteoblast 
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differentiation by activated T cells and how that may differ in HIV-infected T cells.    
Determining the role of T cell activation and HIV infection on osteoblastogenesis 
could open new avenues for the development of therapeutics for not only HIV 
individuals experiencing bone loss but others with chronic immune activation and 
osteoporosis as well.    
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Figure 13 
A.  
 
 
 
 
 
 
 
 
 
B. 
 
Figure 13: T Cell Activation and J-Lat Genome. A). When the T cell receptor 
(TCR)/CD3 complex or the calcium channel present on the cell membrane is 
activated, NFAT relocates to the nucleus.  When CD28 is activated, NF-κB 
relocates to the nucleus.  These transcription factors induce expression of IL-2 
along with TNF, CD40L and RANKL.  B). Genome of the HIV genome expressed 
in the J-Lat clone 15.4 cell line modified from [242].   
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3.2 Results of Activated T Cells Cultured with Osteoblasts 
 
3.2.1 Primary activated CD4+T cells inhibit osteoblast differentiation 
through conditioned media and co-culture model systems 
To evaluate the effect of activated CD4+ T cells on osteoblasts, we utilized a 
human osteoblast cell line (hFOB 1.19) capable of expressing early 
differentiation markers, and human primary CD4+ T cells.  hFOB 1.19 cells 
normally grow at 33 degrees Celsius and will differentiate when placed at 39 
degrees Celsius due to the presence of a temperature sensitive T antigen. The T 
cells were activated for 24 hours using antibodies against CD3 and CD28.  After 
activation, supernatants were collected and filtered and the cells were washed 
and resuspended in fresh media.  The supernatants were added to the 
osteoblasts at a 1:1 ratio and left on for five days.  The 1x106 CD4+T cells were 
added to the osteoblasts for 2 days, washed off, and then the osteoblasts were 
cultured for 3 more days.  At the 5-day time point, the osteoblasts were stained 
for alkaline phosphatase (ALP), a marker of differentiation.  This time point was 
picked since ALP expression can be observed 5 days after initiation of 
differentiation. Figure 14 shows representative images from these experiments.  
The top panel shows the comparison of undifferentiated and differentiated 
osteoblasts, an obvious increase in staining was observed as expected.  The 
middle panel shows the results from the supernatant addition.  The left middle 
panel represents ALP staining after supernatants were added from unstimulated 
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cells.  Compared to differentiated cells, there is no change in ALP staining.  The 
supernatants from the activated cells, however, markedly decrease ALP staining, 
indicating a role for activation in the inhibition of ALP staining.  These results also 
suggest that activated T cells secrete a factor inhibitory for osteoblast 
differentiation.  The bottom panel contains images representative of the co-
culture system.  When unstimulated T cells were added (bottom left), there was 
no significant change in ALP staining.  In contrast, osteoblasts cultured with 
activated T cells were not able to express ALP.  Images were quantified and 
calculated as percent ALP (Figure 14).  Overall, activated CD4+ T cells were 
able to inhibit osteoblast differentiation via conditioned media and co-culture. 
These results address the inhibitory role of activated T cells on osteoblast 
differentiation.   
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Figure 14 
A.  
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B. 
 
Figure 14: ALP Stain of hFOB 1.19 Cells After Primary CD4+ T Cell Addition. 
hFOB 1.19 cells were plated at a density of 1.7x105 per 3.8cm2.  Undifferentiated 
cells were grown at 330C and switched to 390C to induce differentiation. 1x106 
primary CD4+ T cells were activated with 0.1mg/ml anti-CD3 and 1mg/ml anti-
CD28 for 24 hours. Supernatants were collected and filtered before being added 
at a 1:1 ratio with the osteoblasts.  The cells collected were washed and 
resuspended in fresh media and then added to the osteoblast culture.  Once 
supernatants or cells were added, the hFOBs were placed at 390C to induce 
differentiation. Two days after the cells were co-cultured together, the T cells 
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were removed and fresh media was added to the osteoblasts.  ALP staining was 
done 5 days after supernatants were added to the osteoblasts and 3 days after 
the T cells were removed from the co-culture (5 days after T cells were added).  
A). Representative images from 3 independent experiments. B). Images were 
quantified using ImageJ and are represented as averages of percent ALP 
compared to undifferentiated cells.  Students t-test compared ALP staining from 
osteoblasts exposed to unstimulated T cells and activated T cells.   
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3.2.2 JQ1 and rapamycin inhibit primary CD4+T cell activation and 
consequently prevent inhibition of osteoblast of differentiation 
Since we found that only activated CD4+ T cells were capable of inhibiting 
osteoblast differentiation, we speculated that reducing T cell activation would 
prevent this inhibition.  To address this, we utilized the pro-osteogenic and well-
studied antagonist of T cell activation we discovered in chapter 2, rapamycin 
[208, 226, 244].  Concurrent with these studies, we wanted to address the role of 
the novel compound, JQ1, on CD4+T cell activation and subsequent inhibition of 
osteoblast differentiation. Both compounds were used at concentrations of 1µM. 
To determine each compound’s ability to inhibit T cell activation, we treated 
CD4+ T cells for one hour with rapamycin or JQ1.  We then washed out the 
compound and activated the cells for 24 hours.  After 24 hours, the cells were 
collected and RNA was extracted.   We analyzed transcript levels of genes that 
are commonly induced during T cell activation, CD40 ligand, RANKL and IL-2.  
We found that both rapamycin and JQ1 pre-treatment inhibited the upregulation 
of all three transcripts (Figure 15).  
 
Since JQ1 and rapamycin appeared to prevent T cells from activating as 
measured by qRT-PCR, we wanted to determine if this would result in the 
attenuation of the inhibition of osteoblast differentiation mediated by activated 
CD4+T cells.  Similar to the experiments described above, we pre-treated with 
JQ1 or rapamycin and then activated T cells.  Their respective supernatants or 
	  	   83 
cells were added to osteoblasts prior to measuring ALP staining.  Figure 16 
shows the images and respective quantification.  The top images represent 
staining after from supernatant addition and the bottom images represent 
staining after co-culturing the osteoblasts and T-cells.  When T-cells were pre-
treated with rapamycin or JQ1 and then activated, supernatants failed to inhibit 
osteoblast differentiation as measured by ALP staining (top right images).  
However, in the co-culture system, only rapamycin was able to prevent the 
inhibition of osteoblast differentiation.  Although rapamycin and JQ1 inhibit the 
upregulation of RNA transcripts induced by T cell activation to similar levels and 
were both able to attenuate the effect of supernatants on osteoblastogenesis, 
only rapamycin could mitigate inhibition of osteoblastogenesis in the co-culture 
system.   
 
Additionally, we wanted to test the effect of JQ1 and rapamycin alone on the 
osteoblast culture.  Both compounds were added to the cultures and left for 5 
days and then measure for alkaline phosphatase staining.  Interestingly, JQ1 
inhibited osteoblast differentiation whereas rapamycin had no effect.  Figure 17 
shows representative images and the quantified values for percent of alkaline 
phosphatase. This strengthens our observation that JQ1 is protective by 
inhibiting T cell activation and is effectively washed out prior to activation.   
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Figure 15 
A. 
 
B. 
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C.  
 
 
Figure 15: Rapamycin and JQ1 pre-treatment inhibit upregulation of 
transcripts in primary CD4+ T Cells. Primary CD4+ T cells were activated with 
anti-CD3/CD28 antibodies for 24 hours.  Prior to activation, cells were pre-treated 
with 1 µM rapamycin or JQ1 for one hour and then washed out.  RNA was 
collected 24 hours after activation and transcripts were analyzed via qRT-PCR. 
All transcript values were normalized to 18S and the untreated samples; relative 
fold differences were determined using ΔΔCT.  A). Average of CD40 ligand 
transcripts.  B). Average of RANKL transcripts. C). Average of IL-2 transcripts. 
Activated samples were compared to untreated samples for statistical analysis by 
students t-test whereas rapamycin and JQ1 pre-treated samples were compared 
to activated samples.  Average of 3 independent experiments.  
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Figure 16  
A. 
 
B.	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Figure 16: Rapamycin and JQ1 attenuate inhibition of osteoblast 
differentiation mediated by activated primary CD4+ T cells. hFOB 1.19 cells 
were plated at a density of 1.7x105 cells/3.8cm2.  1x106 primary CD4+ T cells 
were pre-treated with 1 µM rapamycin or JQ1 for one hour and then washed out 
prior to anti-CD3/CD28 activation.  24 hours after activation, cells were collected 
and washed while supernatants were filtered.  Cells were added for 2 days and 
then removed.  Supernatants were added at a 1:1 ratio.  ALP staining was done 
5 days after supernatant addition or co-culture.  A). Representative images from 
3 independent experiments.  B). Images were quantified using ImageJ and the 
bar graph represents percent ALP staining.  Students t-test compared 
osteoblasts exposed to unstimulated and activated T cells along with comparing 
JQ1 and rapamycin pre-treatment to activated cells.  Average of 3 experiments. 
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Figure 17 JQ1 inhibits alkaline phosphatase of hFOB 1.19 cells 
hFOB 1.19 cells were plated at a density of 1.7x105 cells/3.8cm2 and treated with 
1 µM rapamycin or JQ1 for 5 days.  A). Representative images from 3 
independent experiments.  B). Images were quantified using ImageJ and the bar 
graph represents percent alkaline phosphatase staining.  Students t-test 
compared undifferentiated to differentiated and JQ1 or rapamycin to 
differentiated.  Bar graph is an average of 3 experiments. 
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3.2.3 T cells expressing the HIV genome enhance the inhibition of 
osteoblast differentiation and cannot be rescued by either JQ1 or 
Rapamycin 
One of the goals of this project was to understand mechanisms that may 
contribute to HIV-associated bone loss.  To determine whether HIV exacerbates 
the osteoblast-T cell communication we took advantage of the J-Lat cell line.  
These cells are Jurkat cells (human T cell line) that have been virally infected 
with an HIV construct without env or nef.  Therefore, these cells constitutively 
express the HIV genome and when they are activated they release non-
infectious HIV particles.    
 
As with the human primary CD4+T cells, we wanted to establish if JQ1 and/or 
rapamycin could inhibit transcripts induced by T-cell activation.  Both Jurkat and 
J-Lat cells were pre-treated with 1µM JQ1 and/or rapamycin for one hour and 
then activated for 24 hours.  After 24 hours, RNA was collected and analyzed.  
We decided to measure IL-2 and TNFα to gauge general activation.  Additionally, 
TNFα has an inhibitory role on osteoblast differentiation, making it a potential 
candidate for the mechanism of inhibition.  When Jurkat cells were pre-treated 
with rapamycin and/or JQ1, IL-2 and TNFα transcripts were both significantly 
inhibited (Figure 18).  Interestingly, neither rapamycin nor JQ1 were able to 
significantly inhibit transcripts in the J-Lat cells (Figure 19).  
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Since it is possible that TNFα is contributing to the inhibition of osteoblast 
differentiation, we measured intracellular protein levels of TNFα in Jurkat and J-
Lat cells.  In both cell types, protein levels decreased with activation, most likely 
due to secretion of the active form of TNFα.  Also, protein levels were decreased 
with rapamycin pre-treatment but not with JQ1 (Figure 20).  This is an 
unexpected effect in the J-Lat cells since rapamycin did not inhibit upregulation of 
TNFα transcripts.  This result along with the transcription data indicates a 
difference in responsiveness to JQ1 and rapamycin between HIV-infected and 
uninfected cells.  It also supports a potential difference in effectiveness of 
inhibition between JQ1 and rapamycin since only rapamycin inhibited protein 
levels and neither could prevent upregulation of transcripts in J-Lat cells.  
 
Using primary CD4+ T cells, we found that JQ1 and rapamycin were capable of 
inhibiting the upregulation of transcripts after T cell activation and therefore could 
attenuate the inhibition of osteoblastogenesis.  Thus far, we have established 
that JQ1 and rapamycin inhibit upregulation of transcripts after T cell activation in 
Jurkat cells but not J-Lat cells.  Therefore, we wanted to determine if this 
difference would remain in the osteoblast-T cell model.  As with the primary 
CD4+ T cell experiments, Jurkat and J-Lat cells were pre-treated with rapamycin 
or JQ1 and then activated.  After 24 hours of activation, supernatants were 
collected and filtered while cells were washed and resuspended in fresh media.  
Supernatants were added to osteoblasts for 5 days at a 1:1 ratio.  Cells were co-
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cultured with osteoblasts for 2 days and then removed.  ALP staining was done 
at the 5-day time point.  Images and quantification of the Jurkat-osteoblast 
experiment are in Figure 21.  Supernatants from activated Jurkat cells inhibited 
upregulation of ALP staining and both rapamycin and JQ1 attenuated the 
inhibition of osteoblast differentiation.  Activated Jurkat cells inhibited 
upregulation of ALP staining when co-cultured with the osteoblasts and only 
rapamycin could attenuate the inhibition of osteoblast differentiation.  These 
results mimic the primary CD4+ T cells experiments.  Results from the J-Lat-
osteoblast experiment are in Figure 22.  Similar to the Jurkat cells, supernatants 
from activated J-Lat cells were able to inhibit osteoblast differentiation as 
measured by ALP staining.  However, neither rapamycin nor JQ1 could 
significantly mitigate the inhibition of osteoblast differentiation.  This correlates 
with the inability of rapamycin and JQ1 to prevent induction of IL-2 and TNFα 
transcripts.  Unexpectedly, when unstimulated J-Lat cells were co-cultured with 
osteoblasts, reduction of ALP staining was observed, indicating an HIV-specific 
effect.  Notably, when osteoblasts were co-cultured with activated J-Lat cells, the 
inhibition of upregulation in ALP staining was due to a complete loss of cells.  No 
cells were observed in the wells, possibly due to apoptosis induced by activated 
J-Lat cells.  Rapamycin and JQ1 failed to reduce the inhibition of osteoblast 
differentiation.  Overall, J-Lats differed from Jurkats by their lack of response to 
JQ1 and rapamycin and their ability to inhibit osteoblasts in co-culture regardless 
of activation.  These are important differences that may affect the development of 
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therapeutics and the consideration that inhibition of T cell activation may not 
have the same effectiveness in different disease states.   
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Figure 18 
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Figure 18: Rapamycin and JQ1 pre-treatment inhibit IL-2 and TNFα 
transcription in Jurkat cells. 1x106 Jurkat cells were pre-treated with 1µM 
rapamycin and/or JQ1 for 1 hour and then washed out prior to activation with 
PMA for 24 hours.  RNA was collected and extracted for analysis via qRT-PCR.  
A). TNFα transcripts and B). Il-2 transcripts were normalized to 18S levels and 
relative fold difference was determined using the unstimulated sample and the 
ΔΔCT method.  Students t-test used, activated samples were compared to 
unstimulated samples and pre-treated samples were compared to activated 
samples.  Average of 3 independent experiments. 
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Figure 19 
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Figure 19: Rapamycin and JQ1 pre-treatment fail to inhibit IL-2 and TNFα 
transcripts in J-Lat cells. 1x106 J-Lat cells were pre-treated with 1µM 
rapamycin and/or JQ1 for 1 hour and then washed out prior to activation with 
PMA for 24 hours.  RNA was collected and extracted for analysis via qRT-PCR.  
A). TNFα transcripts and B). Il-2 transcripts were normalized to 18S levels and 
relative fold difference was determined using the unstimulated sample and the 
ΔΔCT method.  Students t-test used, activated samples were compared to 
unstimulated samples and pre-treated samples were compared to activated 
samples. Average of 3 independent experiments.  
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Figure 20 
 
 
 
 
 
 
 
 
 
 
Figure 20:  Rapamycin inhibits intracellular TNFα protein in Jurkat and J-
Lat cells. 1x106 Jurkat and J-Lat cells were pre-treated with 1µM rapamycin or 
JQ1 for an hour and washed prior to activation with PMA for 24 hours.  After 
activation, cells were pelleted and lysed to extract protein. Protein levels were 
analyzed via Western Blot using primary antibodies against TNFα and β-actin.  
The images were analyzed using ImageJ and the graphs represent percent of 
protein expression as compared to the unstimulated (UT) samples.  The top 
panels represent protein levels from Jurkat cells and the bottom panels represent 
protein levels from J-Lat cells.  
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Figure 21: Rapamycin and JQ1 attenuate inhibition of osteoblast 
differentiation mediated by activated Jurkat cells. 
hFOB 1.19 cells were plated at 1.7x105 cells/3.8cm2.  1x106 Jurkat cells were 
activated by PMA for 24 hours.  Cells were pre-treated with 1 µM of rapamycin 
and/or JQ1 for one hour and washed out prior to activation.  Supernatants were 
collected, filtered and added at a 1:1 ratio to osteoblasts.  Jurkat cells were 
collected and washed prior to co-culturing with osteoblasts for two days.  5 days 
after addition of supernatants or cells, ALP staining was done. A). Representative 
images of hFOBs after supernatant addition and B.) quantified using ImageJ.  C). 
Representative images of hFOBs after co-culture with Jurkat cells and D.) 
quantified using ImageJ.  Students t-test was done comparing staining after 
addition with unstimulated and activated Jurkat cells or pre-treated cells and 
activated cells.  Average of 3 independent experiments. 
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Figure 22 
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Figure 22: Rapamycin and JQ1 fail to attenuate inhibition of osteoblast 
differentiation mediated by activated J-Lat cells. 
hFOB 1.19 cells were plated at 1.7x105 cells/3.8cm2.  1x106 J-Lat cells were pre-
treated with 1µM of rapamycin and/or JQ1 for one hour and washed out prior to 
activation by PMA for 24 hours. Supernatants were collected, filtered and added 
at a 1:1 ratio to osteoblasts.  Jurkat cells were collected and washed prior to co-
culturing with osteoblasts for two days.  5 days after addition of supernatants or 
cells, ALP staining was done. A). Representative images of hFOBs after 
supernatant addition and B.) quantified using ImageJ.  C). Representative 
images of hFOBs after co-culture with Jurkat cells and D.) quantified using 
ImageJ.  Students t-test was done comparing staining after addition with 
unstimulated and activated Jurkat cells or pre-treated cells and activated cells.  
Average of 3 independent experiments.  
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3.3 Conclusions and Discussion of Osteoblast-T Cell Model 
 
3.3.1 Summary of Results 
These experiments suggest that activated T cells are capable of inhibiting 
osteoblast differentiation when cultured together and by conditioned media.  
Unexpectedly, the effect of supernatants was attenuated by JQ1 and rapamycin 
pre-treatment, whereas only rapamycin could mitigate the effect in co-culture.  
Since the compounds are washed out and not present in the co-culture system, it 
is likely a cell-cell specific effect.  It is possible that osteoblasts signal to the T 
cells, subsequently altering their response to the compounds and therefore 
resulting in different efficacies.  This was observed for both human primary CD4+ 
T cells and Jurkat cells.  JQ1 and rapamycin were also able to inhibit IL-2 
transcription in both cell lines along with RANKL and CD40L in primary cells and 
TNFα in Jurkat cells.  The compounds failed to attenuate the effect of J-Lat 
activation on inhibition of osteoblast differentiation along with induction of 
transcripts by activation.  Interestingly, J-Lat cells inhibited osteoblast 
differentiation in the co-culture system without activation.  Notably, rapamycin, 
not JQ1, was able to inhibit intracellular protein levels of TNFα in both cell types.  
This data underscores that secreted factors and contact-dependent molecules 
are involved in the regulation of osteoblast activity by immune cells.   
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3.3.2 Potential Mechanism of Inhibition 
T cells and osteoblasts have been found to communicate through several 
different mechanisms.  The following studies have indicated that pro-
inflammatory factors secreted from activated T cells induce signaling in 
osteoblasts.  One potential mechanism involves TNFα, which is secreted when 
CD4+T cells become activated [245, 246]. Separate studies have found that 
TNFα is inhibitory to osteoblast differentiation.  TNFα has been found to inhibit 
osteoblast differentiation by promoting the degradation of Runx2 and BMPs, 
essential factors for the progression of osteoblast differentiation [247, 248] along 
with interfering in the DNA binding of Smads, transcription factors that induce 
osteoblast differentiation [249].  A recent compelling study found that TNFα and 
IFNγ produced by activated T cells inhibit the ability of bone marrow 
mesenchymal stem cells to mediate bone repair via activation of caspase-3 and -
8, leading to induction of apoptosis [250]. Since we saw an increase in TNFα 
transcripts with activation in human primary CD4+ T cells and T cell line (i.e. 
Jurkats) and subsequent reduction with rapamycin and JQ1, it is possible that 
TNFα contributes to the inhibition of the upregulation of ALP staining in 
osteoblasts exposed to activated T cells. IFNγ may also contribute to this 
inhibition as it has also been found to be inhibitory of osteoblast differentiation.  A 
study found that antibodies against IFNγ blocked the inhibitory effect of 
supernatants from activated T cells on osteoblasts [151].  Pro-inflammatory 
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cytokines, including TNFα and IFNγ, produced by activated T cells most likely 
contribute in our observed osteoblast inhibition. 
 
3.3.3 Rapamycin and HIV 
HIV-infected individuals are susceptible to both infectious and non-infectious 
comorbidities along with an increased incidence of transplant rejection.  
Rapamycin has been given to HIV patients in several studies to determine its 
efficacy in preventing transplant rejection and reducing immune activation.  The 
mTOR signaling pathway is often dysregulated in cancer, including Kaposi’s 
sarcoma, the most commonly diagnosed AIDS-defining cancer.  One study 
wanted to evaluate the efficacy, safety and toxicity of rapamycin in HIV-patients 
with Kaposi’s sarcoma.  They found that rapamycin was safe to give to these 
patients and that the tumor regression was induced in some of them [251].  
There have also been studies focusing on the role of rapamycin in transplants 
being received by HIV-infected individuals.  One study looked at the role of 
rapamycin in liver transplants of HIV and hepatitis C (HCV) co-infected 
individuals. Interestingly, this group found evidence that rapamycin treatment 
controlled HIV and HCV replication along with long-term immunosuppression 
maintenance [252].  In vitro studies have also looked at the role of rapamycin in 
HIV infection and found that rapamycin prevents HIV-infection and replication by 
downregulating the co-receptor CCR5 [253-257]. Correlating with the findings 
that inhibition of T cell activation by rapamycin reduces HIV replication, one 
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group found that HIV-infection was inhibited in human peripheral blood 
leukocytes that were transplanted into immunocompromised mice, indicating that 
lack of T cell activation is detrimental for HIV propagation [253]. Overall, 
rapamycin has safely been given to HIV patients and has a range of positive 
effects; therefore, rapamycin has been considered as an additional anti-retroviral 
therapeutic [258].   
 
3.3.4 Overall Conclusion and Limitations 
This study was focused on identifying differences between uninfected and HIV-
infected activated T cells on osteoblasts. Consequently, it revealed that the 
communication between osteoblasts and T cells could vary between different 
diseases.  For HIV-associated bone loss, it is possible that the HIV accessory 
proteins, specifically Tat, contribute to the inhibition of osteoblast differentiation in 
addition to chronic immune activation.  This would not be applicable to other 
chronic immune activation diseases, such as rheumatoid arthritis.  Activated T 
cells were able to inhibit osteoblast differentiation but T cell activation antagonists 
were not effective in the HIV model.  The observation that T cell activation 
antagonists were not effective in the HIV model underscores the need for novel 
therapeutics that disrupt the effect of activated T cells on osteoblast 
differentiation in HIV infection. Figure 23 summarizes our data for each cell type 
and the effect of JQ1 and rapamycin.  
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Our supernatant and co-culture model will be useful in identifying mechanisms 
and compounds that are specifically relevant in HIV infection.  Understanding the 
general pathways and mechanisms involved in the inhibition of osteoblast 
differentiation by activated T cells is critical to determine the differences in 
inhibition of osteoblast differentiation caused by HIV infection.  Interestingly, most 
HAART treated individuals do not have detectable levels of virus, indicating a 
potential intrinsic difference, such as distinctive cell surface molecules, between 
T cells in HIV patients and healthy patients.  It would be informative to isolate T 
cells from treated HIV-infected individuals and age-matched uninfected controls 
and assess their ability to inhibit osteoblast differentiation. It would also be 
relevant to determine the ability of JQ1 and rapamycin to attenuate the inhibition 
by activated T cells from HIV-infected individuals. Unraveling the causation of 
HIV-associated bone loss will help identify mechanisms that could be relevant in 
other diseases with increased immune activation.   
 
Although we established that activated T cells could inhibit osteoblast 
differentiation and that HIV infection prevented response to 
immunosuppressants, there were limitations to this study.  We determined 
activation of T cells by measuring transcription levels of known genes that are 
upregulated during activation, including IL-2 and TNFα. To confidently establish 
that activation is occurring and then inhibited by immunosuppressants, we would 
need to measure other markers of activation.  Often, T cell activation is 
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measured by quantifying the cell surface molecules CD25 and CD71.  J-Lat cells 
express GFP when activated and therefore the levels of GFP could be measured 
to determine activation. A functional assay could also be used, where IL-2 levels 
can be measured by a luciferase assay.  Confirming activation and subsequent 
inhibition by rapamycin and/or JQ1 would strengthen our claim that activated T 
cells inhibit osteoblast differentiation and that this can be attenuated with 
rapamycin or JQ1.  We also did not do a dose response of JQ1 and rapamycin to 
determine at what concentrations they are effective at both inhibiting T cell 
activation and attenuating inhibition of osteoblast differentiation.  It is possible 
that the J-Lat cells would have been inhibited by rapamycin and JQ1 at a higher 
concentration.  We also only looked at one time point after activated T cells or 
their supernatants were added.  Looking at other times points and markers of 
differentiation, such as Runx2 and Osx, may have established the kinetics of 
inhibition.  Another limitation to this study was the use of only one model for HIV 
infection.  Using a different latently infected T cell line AcH2s, along with latently 
infected T cells from treated patients, would have confirmed our results.  Our 
study lays the groundwork needed to further understand the relationship between 
activated T cells and osteoblasts as well as the role of HIV infection. 
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Figure 23 
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Figure 23: Model of osteoblast-T cell Results. Panel A represents the model 
of the effect of supernatants from uninfected human primary CD4+ T cells and 
Jurkat cells on osteoblast differentiation as measured by ALP staining and the 
attenuation of the inhibition by JQ1 or rapamycin.  Panel B represents the model 
of the effect of co-culture from uninfected human primary CD4+ T cells and 
Jurkat cells on osteoblast differentiation as measured by ALP staining and the 
attenuation of the inhibition by rapamycin, not JQ1.  Panel C represents the 
model of the effect of both supernatants and co-culture of J-Lat (HIV-infected) 
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cells on osteoblast differentiation and the failure of JQ1 or rapamycin to attenuate 
the inhibition of differentiation.   
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3.4 Future Directions to Identify Mechanisms of Osteoblast-T Cell Crosstalk 
 
3.4.1 Role of TNFα and Apoptosis 
This data focuses on the ability of activated T cells to inhibit osteoblast 
differentiation and how HIV-infected T cells may affect the inhibition similarly or 
differently. It is reasonable to suggest that TNFα is an important player in this 
model system.  To test this we would want to measure the levels of TNFα in the 
supernatant of activated T cells using ELISA and to use antibodies against TNFα 
to neutralize the effect.  It would also be informative to genetically delete TNFα in 
T cells and see if inhibition of osteoblast differentiation persists after T cell 
activation.  We would expect that supernatants from activated T cells have higher 
levels of TNFα compared to unstimulated T cells and that supernatants from T 
cells treated with JQ1 and rapamycin would have lower levels.  We would also 
expect HIV-infected T cells to secrete higher levels of the protein and that these 
levels would not change with JQ1 or rapamycin treatment, explaining some of the 
differences we observed.  It is unlikely that TNFα is the only protein inhibiting 
osteoblast differentiation and therefore analyzing the secretome would identify 
other potential mechanisms involved.   
 
Prior to identifying the mechanisms involved, it is beneficial to test our model 
using either primary human bone marrow cells or mesenchymal stem cells that 
are capable of mineralizing and terminally differentiating.  Since the hFOB 1.19 
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cell line failed to mineralize, primary cells would give insight into determining if 
the inhibition mediated by activated T cells is potent enough to inhibit late 
differentiation as well as early differentiation. Identifying the point at which 
inhibition occurs and how long it is effective will add to the body of knowledge.  
Although we established that activated T cells inhibit osteoblast differentiation, 
the mechanism of action remains unknown.  It is rational to propose apoptosis as 
a mechanism since TNFα has been shown to induce apoptosis in osteoblasts.  
There are several ways to measure apoptosis.  Flow cytometry can detect 
apoptotic cells by measuring annexin V, which will bind to phosphatidylserine on 
the cell surface, an indicator of apoptosis.  Terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) detects DNA fragmentation, another result of 
apoptotic signaling.  Caspase-3 and -8 are induced during apoptosis and 
therefore can also be measure through a variety of assays, including western blot 
and ELISA.  These methods would determine any involvement of apoptosis in 
the inhibition of osteoblast differentiation.  Inhibition of osteoblast differentiation 
may also be a result of impaired signaling within the cells.  Analyzing the 
pathways involved in differentiation, such as the BMP-2 signaling cascade, will 
determine if there is also a block in the induction of differentiation.   Analyzing the 
methods by which activated T cells inhibit osteoblast differentiation will contribute 
to the development of effective approaches that prevent the negative effects of 
the immune system on bone homeostasis.   
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3.4.2 Analyze secreted and cell surface molecules in HIV-infected and 
uninfected T cells 
Inhibition of osteoblast differentiation by HIV-infected activated T cells displays a 
more severe phenotype due to the depletion of osteoblasts in the co-culture 
system and inability to be attenuated; however, the mechanisms are unclear.  A 
secretome analysis of the supernatants from HIV-infected T cells may reveal a 
separate effector protein involved compared to uninfected cells that cannot be 
attenuated by rapamycin or JQ1.  Measuring T cell activation by flow cytometry 
or by IL-2 protein production would also help determine if JQ1 and rapamycin fail 
to attenuate activation completely or if an activation-independent mechanism is 
involved.  Additionally, it is uncertain if activation of HIV-infected T cells cannot 
be inhibited; therefore using other antagonists of T cell activation would add to 
the knowledge developed here.  FK-506 and mycophenolic acid might reveal that 
inhibition of T cell activation in HIV-infection can be obtained through a different 
mechanism.   
 
An unexpected finding was that J-Lat cells were capable of inhibiting osteoblast 
differentiation in the co-culture model without being activated.  This indicates an 
intrinsic difference in these cells compared to the Jurkat and primary CD4+ T 
cells, most likely on the cell surface since supernatants from unstimulated cells 
did not give the same result.  To identify this, we would do a microarray of RNA 
from Jurkat and J-Lat cells.  Comparing primary CD4+ T cells from uninfected 
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and HIV-infected individuals would also identify intrinsic differences that could 
inhibit osteoblast differentiation.  If differences were found, then that would 
partially explain the increased incidence of bone loss in HIV-infected individuals.   
 
In Chapter 2, we developed a novel high-throughput screening method that could 
identify modulators of osteoblast proliferation and differentiation.  It would be 
useful to modify this method to find compounds that could disrupt the inhibition of 
osteoblast differentiation mediated by activated T cells for both HIV-infected and 
uninfected cells.  Identifying compounds capable of preventing this inhibition 
would be beneficial for developing novel therapeutic options as well as reveal 
pathway and mechanism of action differences between HIV-infected and 
uninfected T cells.   Further studies into how T cells communicate with 
osteoblasts and how that might differ in various disease states may open new 
treatment avenues.   
 
 
 
 
 
 
 
 
	  	   119 
Chapter 4: Discussion and Implications of Immunosuppressants Perturbing 
Osteoblast Differentiation 
 
4.1 Summary of Results  
 
In this dissertation, we hypothesized that T cell activation inhibits osteoblast 
differentiation, underlying HIV-mediated bone loss, and is attenuated by 
immunosuppressants.  We addressed this in three different aims.  Our first aim, 
carried out in Chapter 2, was to develop a novel high-throughput screen that was 
capable of identifying modulators of osteoblast differentiation.  After completing 
the high-throughput screen, we found that the most interesting modulators were 
those that induced osteoblast differentiation, as they have potential for 
therapeutic use.  Our screen utilized the C2C12 mouse muscle stem cell line 
since only 30% of the cells converted to the osteoblast lineage in the presence of 
bone morphogenetic protein-2 (BMP-2) and had insignificant background when 
stained for alkaline phosphatase (ALP).  These characteristics allowed us to 
easily identify any changes in ALP staining or overall morphology.  Our screen 
identified 18 inducers of osteoblast differentiation and we validated rapamycin 
and FK-506 as proof-of-concept.  We also utilized these compounds in a 
challenge model and found that rapamycin could prevent inhibitory effects due to 
TGFβ.  
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Our second and third aims focused on the role of T cell activation on osteoblast 
differentiation and found that human primary CD4+ T cells, Jurkat and J-Lat cells 
(latently infected with HIV) inhibited osteoblast differentiation when activated, 
through co-culture and addition of supernatants.  Interestingly, J-Lat cells were 
also able to inhibit osteoblast differentiation in the co-culture system when 
unstimulated, indicating a potential intrinsic difference between uninfected and 
HIV-infected T cells.  Since our high-throughput screen identified 
immunosuppressors as inducers of osteoblast differentiation, we wanted to utilize 
them in our model system.  Also, since inhibition of osteoblast differentiation was 
induced when T cells were activated, we made the logical hypothesis that 
antagonists of T cell activation would attenuate this effect.  Rapamycin, a known 
immunosuppressant, along with JQ1, a novel inflammatory inhibitor, both 
attenuated the inhibition of osteoblast differentiation mediated by T cell activation 
in supernatants from human primary CD4+ T cells and Jurkat cells.  JQ1 failed to 
attenuate in the co-culture system for both cell types. The compounds also 
inhibited IL-2 transcription in both cell types and CD40LG and RANKL in primary 
cells along with TNFα in Jurkats.  In contrast, rapamycin and JQ1 failed to 
attenuate inhibition of osteoblast differentiation mediated by activated J-Lat cells 
and also failed to inhibit IL-2 and TNFα transcription due to activation.  This data 
suggests that HIV-infection has a significant effect on the cell’s ability to have its 
activation inhibited.   
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4.2 Mechanisms and Application of Rapamycin  
Although rapamycin is commonly thought of as an immunosuppressor and is 
approved by the FDA for this application, it has become a widely used compound 
for a variety of applications in research.   This compound inhibits mTOR, an 
important regulator of cell functions, including protein translation [208].  Although 
we found that rapamycin can enhance osteoblast differentiation, other studies 
contradict this finding and have found other activities.  Relevant to our results, 
rapamycin has been shown to inhibit HIV replication whereas FK-506 cannot 
[259]. Rapamycin’s clinical relevance in HIV has been studied in small groups of 
patients, and they support the general finding that it is able to reduce HIV 
replication, mostly due to reduction of the HIV co-receptor CCR5 [251, 252, 258]. 
It has also been found to reduce HIV-associated neuropathy [260].  
 
Rapamycin is well known for its ability to induce autophagy [261].  Autophagy is 
the mechanism by which the cell degrades unnecessary or dysfunctional 
components via lysosomes and can increase cellular survival under stressful 
conditions, such as starvation [262].  This has been an important topic to study 
as it plays an important role in the development of cancer and inducing 
autophagy has become a potential therapeutic.  Rapamycin has been found to 
induce autophagy and consequently apoptosis in many cancer cells, including 
pancreatic cancer [263], glioblastoma [264] and melanoma [265] as examples. 
Interestingly, rapamycin can also sensitive cancer cells to the effects of 
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chemotherapy and radiation, making it a useful cancer drug [266-268]. Due its 
ability to inhibit cancer cell growth, a derivative of rapamycin, temsirolimus 
(Torisel) was developed by Wyeth and approved by the FDA in 2007 to be used 
in conjunction with other anti-cancer drugs and has been found to induce 
autophagy (FDA [269, 270]. Inducing autophagy can be beneficial for other 
diseases besides cancer.  Delivery of rapamycin via nanoparticles in mdx mice 
(muscular dystrophy phenotype) was found to be efficient in restoring autophagy 
and consequently increases skeletal muscle strength and cardiac muscle 
contractility [271]. Impairment of autophagy has also been found to contribute to 
the development of cystic fibrosis [272]. Addressing the role of autophagy in 
various disease types could result in expanding the clinical usage of rapamycin. 
 
 
4.3 Mechanisms and Application of JQ1 
Bromodomain-containing proteins, such as BRD4 and BRD2, bind to acetylated 
lysine residues, commonly found on modified histones.  Their role in chromatin 
remodeling is critical in regulating gene expression.  JQ1 inhibits binding of 
BRD4 to the chromatin and is therefore responsible for a variety of changes in 
gene expression.  James Bradner’s group was the first to report the development 
of JQ1 and its ability to competitively bind to acetylated lysine residues as well as 
force differentiation and stop proliferation of human squamous carcinoma cells 
[273].  Inhibiting bromodomains has become an effective method in preventing 
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cancer cell growth by targeting c-myc, a protein often mutated and therefore 
upregulated in cancer, since its transcription is regulated by BRD4, making it a 
viable option for therapy [274-277].   
 
Recently it has been reported that JQ1 can reactivate HIV transcription in latently 
infected cells [278, 279]. One group found that JQ1 leads to an increase of free 
P-TEFb allowing for BRD4-P-TEFb complexes to form and increase HIV 
transcription [280]. Another group found that when JQ1 dissociated BRD4 from 
the HIV promoter, it allows Tat to recruit the Super Elongation Complex (SEC) 
and promote HIV elongation. This group also found that JQ1 acts synergistically 
with prostratin, an inducer of Pol II loading onto the viral promoter [281].  
Contradicting this study, another group found that the mechanism of JQ1 was 
Tat-independent and suggested BRD2 is involved in establishing HIV latency 
[282].  Regardless of mechanism, JQ1 is a promising molecule for the initiative to 
cure HIV infection.     
 
Bromodomain-containing proteins have global effects on chromatin remodeling 
for a variety of genes and therefore JQ1 may be useful in other diseases besides 
cancer and HIV where genes are dysregulated.  Interestingly, JQ1 was reported 
to reduce sperm motility and levels in mice, making it a potential male 
contraceptive [283].  Another group reported that JQ1 ablates cytokine 
production in mouse macrophages [243]. This, along with our data, supports the 
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notion that JQ1 has anti-inflammatory properties and could be useful in chronic 
inflammatory conditions, including HIV infection and rheumatoid arthritis.   
 
4.4 Limitations and Future Directions  
This study aimed to establish a role of T cell activation in osteoblastogenesis.  
Although we found that human primary CD4+ T cells, along with the T cell lines 
Jurkat and J-Lat, inhibited osteoblast differentiation mediated by T cell activation, 
we did not determine a mechanism of action. The loss of alkaline phosphatase 
staining could be due to apoptosis or a blockade in signaling pathways, but our 
data does not indicate which.  We also only looked at one marker of osteoblast 
differentiation and it was at a relatively early time point.  Osteoblast differentiation 
and matrix deposition takes approximately 21 days and we only measured 
differentiation after 5 days.  The hFOB 1.19 cells failed to mineralize in culture 
and therefore we could not measure later time points of differentiation.  Although 
we only looked at an early time point of differentiation, it would have been 
beneficial to look at other markers, including Runx2 and Osx protein and 
transcription levels.  Looking at other markers of differentiation may have given 
us an insight into what the mechanism of inhibition is.  We also did not look at the 
kinetics of inhibition.  We focused on one time point and did not add the 
supernatants or cells at varying levels.  It would be interesting to determine if the 
activated T cells are only effective in certain cell numbers and when inhibition 
occurs.  Although we can state that activated T cells inhibit osteoblast 
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differentiation, we cannot conclude on how this happens and what parameters 
are required, such as concentration and time.  Our overall hypothesis stated that 
T cell activation inhibits osteoblast differentiation, underlying HIV-mediated bone 
loss, and is attenuated by immunosuppressants.  Although we have shown that T 
cell activation inhibits osteoblast differentiation and that this is attenuated by 
immunosuppressants, we did not carry out experiments focused on general bone 
loss.  There are several model systems we could use that would address this and 
they are described below.  
 
HIV-associated bone loss is difficult to study in vivo since HIV does infect 
rodents, which are typically used for in vivo studies.  However, researchers have 
tried to overcome this and have developed two model systems that we could 
potentially use.  The HIV transgenic rat has been developed, where the HIV 
provirus, minus gag and pol, is present throughout the animal, and experiences 
many AIDS-related complications, including respiratory difficulty, neurological 
signs, wasting and skin lesions [284].  These animals also experience bone loss 
around 6 months of age, reported to be caused by an increase of RANKL 
production and therefore increased osteoclast bone resorption [285].  To further 
explore the potential of activated T cells to inhibit osteoblast differentiation, it 
would be interesting to use T cells and osteoblasts from these rats and conduct 
our experiments compared to healthy wild type rats.  Although this report 
indicates a role for osteoclasts in bone loss, it fails to look at the contribution of 
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osteoblasts.  We could also add JQ1 and/or rapamycin to these rats and look for 
any inhibition of bone loss.  Since the J-Lat cells did not respond to JQ1 and 
rapamycin pre-treatment it is possible that bone loss would not be inhibited in 
these rats.  However, this transgenic rat model could be used to test other 
compounds that would attenuate bone loss due to T cell activation.  Although the 
HIV transgenic rat is not a perfect model, it is a way to study HIV-associated 
comorbidities in vivo and has provided useful data.  Another interesting rodent 
model developed to study HIV is the humanized mouse.  These mice are 
immunodeficient and capable of receiving human lymphocytes, susceptible to 
HIV infection [286].  This allows researchers to study HIV infection in a mouse 
model.  Studies have not been done to look at bone loss in this HIV model 
system and therefore it could be used to further test our hypothesis.  Importantly, 
it would have to be established that these mice experience bone loss and what 
the kinetics are of this development.  We could then test the functionality of 
osteoblasts from these cells ex vivo to determine their ability to deposit bone 
matrix.  Assessing this would be useful in establishing the state of osteoblasts in 
HIV infection.  It would also be useful to add JQ1 or rapamycin to these HIV-
infected mice and measure bone mineral density to determine any inhibition in 
bone loss.  These two rodent models would be very useful in further establishing 
inhibition of osteoblast differentiation mediated by activated T cells and 
contributing to overall bone loss.  Although HIV is also studied in monkeys using 
SIV (simian immunodeficiency virus), there is no evidence that these animals 
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experience bone loss and therefore would not be useful in further studying our 
hypothesis. 
 
Although rodent models have the ability to provide insight into the mechanisms 
involved in HIV-associated bone loss, it would be more informative to establish 
these mechanisms in HIV infected individuals.  Additionally, identifying which axis 
of bone remodeling is dysregulated, osteoblasts versus osteoclasts, would 
provide novel therapeutic targets.  This could possibly be delineated by the 
measurement of biomarkers in the serum.  Common bone turnover markers 
include OCN, P1NP, CTx, TRAP5b, TNFα, RANKL and OPG. Before the advent 
of HAART, bone biopsies revealed markedly suppressed bone formation and 
resorption that correlated directly with severity of infection [287]. Serum OCN 
was also low, reflecting histologic parameters and disease severity (based on 
CD4 count) [288]. Serum CTx, an indicator of osteoclast activity, increased with 
advancing severity of HIV, suggesting disrupted coupling of formation and 
resorption [289]. In contrast, OCN and other bone turnover markers are higher in 
subjects on HAART, suggesting partial but incomplete recovery of osteoblast 
function [290].  These studies indicate abnormal function in both osteoblasts and 
osteoclasts, making them both necessary targets for therapy. 
 
Our data suggests that T cell activation inhibits osteoblastogenesis and 
contributes to bone loss.  This is relevant for several different diseases where 
	  	   128 
chronic immune activation results in reduced bone mineral density.  Patients with 
rheumatoid arthritis have low bone mass and chronic immune activation.  The 
immune system attacks the joints and leads to swelling and pain and eventually 
bone loss [120].  Similar to studies focused on the development of osteoporosis, 
bone loss in rheumatoid arthritis is attributed to an increase in osteoclast activity.  
Recently, studies have shifted focus to the inhibition of osteoblast differentiation 
and activity [291].  Further understanding the role of activated T cells in 
osteoblastogenesis in rheumatoid arthritis may be beneficial to studying HIV-
associated bone loss.  We found that uninfected activated T cells inhibit 
osteoblast differentiation but that this attenuated by JQ1 and rapamycin pre-
treatment.  Using these compounds in an in vivo rheumatoid arthritis mouse 
model could strengthen our observation.  Treating these mice and measuring 
bone mineral density would be important in establishing a therapeutic use for 
immunosuppressants in bone loss mediated by chronic inflammation.   
 
4.5 Translational Implications of Perturbing Osteoblastogenesis 
This dissertation emphasizes the knowledge gap in the understanding of HIV-
associated bone loss.  Current treatments for reduced bone density focus on 
inhibiting osteoclast differentiation and activity. Recently, focus is shifting to 
enhance osteoblast differentiation to deposit new bone matrix and repair bone 
loss.  Our high-throughput screen can be utilized to identify novel therapeutics 
that will induce osteoblast differentiation.  Our screen identified several 
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immunosuppressors, accentuating the need to explore the activities of approved 
drugs.  In addition to our high-throughput screen, we identified the potential 
effects of T cell activation on osteoblast differentiation and found it to be 
inhibitory for expression of alkaline phosphatase.  This could be attenuated with 
the pre-treatment of JQ1 and rapamycin, inflammatory antagonists.  Importantly, 
we established this in HIV-infected T cells and that they are not susceptible to the 
same treatments uninfected cells are.   
 
Overall we aimed to study the concept that chronic inflammation contributes to 
bone loss through the inhibition of osteoblast differentiation.  This notion was 
strengthened by a separate study we conducted, explained in Appendix A and 
referenced [292].  In this study, we aimed to find a correlation between poor 
physical function and inflammatory biomarkers.  We found that HIV positive 
women who were unable to perform physical functions tests had higher serum 
levels of IL-6.  Although we cannot directly attribute the poor physical function to 
bone loss, it is most likely a contributing factor.  It would be interesting to 
measure the bone mineral densities of these women and determine a correlation 
between poor physical function, inflammatory biomarkers and bone loss.  It is 
has been established that treated HIV positive individuals have higher levels of 
immune activation compared to uninfected controls.  Studies are now focusing on 
how this chronic immune activation may be detrimental for overall health in these 
patients.   
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Our data underscores the need for understanding disease specific associated 
bone loss. The effectiveness of JQ1 and rapamycin may be useful in mediating 
bone loss in rheumatoid arthritis but not in HIV infection.  It would also be 
beneficial to further understand the mechanisms contributing to bone loss in 
these chronic immune activation conditions.  We propose a role for osteoblast 
inhibition in the development of bone loss and we have described several ways 
in which this can be further studied.  Although research in this area must 
progress before establishing new treatment options, we are confident that our 
data will contribute to this field.  
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Chapter 5: Materials and Methods 
 
5.1 Cell Culture  
 
5.1.1 C2C12-mouse myoblast cell line 
The C2C12 mouse myoblast cell line (ATCC #CRL-1772) was maintained in 
growth medium (GM) that consisted of high glucose DMEM (Gibco # 11965118), 
10% fetal bovine serum (Gibco # 16000044), and 1% penicillin/streptomycin 
(Invitrogen # 15070063). To induce osteoblast formation, cells were allowed to 
reach 50% confluency, washed with PBS (1X) and switched to differentiation 
medium (DM) that consisted of low glucose DMEM, 2% horse serum (Gibco # 
11885076 and #26050088), 1% penicillin/streptomycin and lyophilized bone 
morphogenetic protein-2 (BMP-2) (Genscript #Z00327), reconstituted in 20 mM 
acetic acid, at a concentration range of 20–200 ng/mL. Negative controls were 
switched to DM but only received 20 mM acetic acid. Cells were passaged 
approximately every two days and were kept below 70% confluency, as per 
manufacturer's instructions. 
 
5.1.2 MC3T3-E1-mouse osteoblast cell line 
MC3T3-E1 subclone 4 mouse pre-osteoblast cells (ATCC #CRL-2593) were 
maintained in minimum essential medium, alpha modification (Invitrogen 
#A10490-01) containing 10% FBS and 1% penicillin/streptomycin. 
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Supplementing the medium with 100 ng/mL BMP-2 induced osteoblast 
differentiation. All cell lines used were maintained in a 37 °C incubator at 5% 
CO2. 
 
5.1.3 hFOB 1.19-human osteoblast cell line 
hFOB 1.19 is a human osteoblast cell line (ATCC #CRL-11372) with a 
temperature sensitive T-antigen.  They were maintained in a 1:1 mixture of 
Ham’s F12 Medium and Dulbecco’s Modified Eagle’s Medium (Life Technologies 
#11039021) with 10% FBS, 1% penicillin-streptomycin and 0.3mg/ml G418 (Life 
Technologies #11811023). Cells were grown at a permissive temperature of 
33.50C with 5% CO2.  To induce differentiation, cells were plated at 1.7x105 
cells/3.8 cm2 and grown at 39.50C with 5% CO2.  
 
5.1.4 Jurkat, J-Lat and Human Primary CD4+ T Cells 
Jurkat, clone E6-1 was obtained from ATCC (#TIB-152).  J-Lat full length clone 
15.4 (#9850) was obtained from AIDS Reagent and is a Jurkat cell line virally 
infected with full length HIV minus env and nef, construct HIV-R7/E-/GFP.  
Primary CD4+ T cells were isolated from human leukopaks using Histopaque-
1077 (Sigman Aldrich #10771-500) to isolate peripheral blood mononuclear cells 
(PBMCs).  CD4+ T cells were isolated from the PBMCs using magnetic 
separation with negative selection CD4+ beads (Miltenyi Biotec #130-094-155).  
All three cell types were maintained in RPMI-1640 (Life Technologies 
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#11875119) medium with 10% FBS, 2.5mM L-glutamine (Life Technologies 
#25030081) and 1% penicillin-streptomycin and grown at 370C with 5% CO2.  
 
5.2 High-Throughput Screen 
 
5.2.1 Chemical Libraries 
Chemical libraries used in this study were prepared by the Center for Molecular 
Discovery at Boston University Medical Center. The libraries consisted of 640 
FDA approved compounds (Enzo Life Sciences), 480 ICCB known bioactive 
compounds (Enzo Life Sciences), 446 compounds from the NIH Clinical 
Collection (BioFocus DPI), ~2000 natural-like compounds from the Center for 
Chemical Methodology and Library Development at Boston University, and a 
diversity subset of 2000 compounds (ChemBridge). 
 
5.2.2 BMP-2 and Compound Stimulation 
384-square well plates (Fisher Scientific #08772000) were used for primary 
screening. PBS was added to the outermost wells to reduce edge effects. In 
each plate, 40 wells were used as positive controls, 28 wells were used as 
negative controls, and the center 240 wells were used for compound testing. All 
plates were screened in duplicate. The inner 308 wells received 750 cells per 
well and were allowed to adhere in GM for 24 hours. GM was then removed, 
wells were washed once with PBS, and DM was added to the inner 308 wells. 
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Negative control wells received DM. Positive control wells received BMP-2 in 
DM. Test wells received BMP-2 and compounds at a target concentration of 1 
µM. DMSO was used as the vehicle for compound addition in this study. DMSO 
was also added to positive and negative control wells in equimolar amounts.  
 
5.2.3 ALP and DAPI Staining  
Cells were initially fixed with a fixative solution that consisted of a 3:10:26 ratio 
mixture of 37% formaldehyde:citrate:acetone. Colorimetric detection of 
osteoblasts was achieved using the alkaline phosphatase (ALP) kit obtained from 
Sigma-Aldrich (Catalog #86C). Cell number was determined based on nuclei 
staining with DAPI nucleic acid stain (Invitrogen). 
 
5.2.4 Image Acquisition and Analysis 
Well images identifying ALP+ cells were acquired using a MIAS-2 plate reader 
(Digilab, Holliston, MA). Acquired images were assessed using three different 
search strategies (ImageJ software, Digilab software, and systematic scanning 
by eye); each having different sensitivities and specificities with regard to this 
assay. 
 
5.2.5 ImageJ Analysis 
Well images were opened with the image software platform ImageJ. Images 
were normalized on a per plate basis and, since ALP positive cells become 
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darker in a gray scale image, the image darkness was assessed. Images were 
analyzed using an Area Fraction method whereby a minimum pixel darkness 
threshold was applied for all image wells. All pixels that were as dark or darker 
than the threshold applied were converted to black. All pixels that did not meet 
the threshold were converted to white. The binary image was then assessed to 
see percentage of pixels of the image that were black (i.e. Area Fraction). 
Average Area Fraction from duplicate compound wells was divided by average 
duplicate nuclei count (as measured by DAPI count in ImageJ) to get Area 
Fraction on a per-cell basis. This ratio (Area Fraction: Nuclei count) was then 
compared to positive control wells. Ratios for the positive control wells, per plate, 
were determined and any compound wells that were greater than three standard 
deviations above the average ratio of positive control wells were considered 
potential augmenters of bone formation and were compared with the two other 
search strategies. 
 
5.2.6 Digilab Analysis 
Well images were analyzed using eaZYX Image Analyzer software (Digilab, 
Holliston, MA). Cell number was determined by counting the number of DAPI 
stained nuclei per image. Fluorescent nuclei images were overlaid with the 
bright-field images to determine the number of ALP positive cells per well. 
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5.2.7 Visual Inspection Analysis 
The image of a representative positive control was kept open for comparison 
while visually scanning the images of wells that had compounds added. Wells 
were rated categorically on a four-point scale: (1) clear augmenter of ALP 
expression, (2) potential augmenter that appeared to have ALP expression 
above the representative positive control, (3) changes in the morphology of the 
cells, and (4) did not change or suppressed ALP expression. Duplicate wells that 
were independently confirmed by eye for increased ALP expression were 
compared with the other two search strategies. 
 
5.3 Quantitative RT-PCR 
Total RNA was extracted by the TRIzol method as recommended by the 
manufacturer (Invitrogen). 1ml of Trizol was used to lyse and collect the cells.  
200uL of chloroform was added to the Trizol and vertexed prior to spinning at 
9800rpm for 15 minutes at 40C.  The upper phase was extracted and added to 
500uL of isopropanol for precipitation at 2-00C for several hours.  After 
precipitation, the samples were spun again at 9800rpm for 15 minutes at 40C to 
get a pellet of RNA.  The pellet was washed with 75% ethanol and then dried 
before resuspension in RNase free water, usually 40uL. RNA was quantified 
using the NanoDrop equipment.  500 ng of RNA was reverse-transcribed using 
the High Capacity cDNA Synthesis Kit (Applied Biosystems #4368813). Taqman 
expression assays were used for detection. The expression of 18S (Applied 
	  	   137 
Biosystems #4319413E) was used for normalization of gene expression values. 
Real-time primers Runx2, Sp7 (Osx), Bglap1 (Ocn) and Smad 7 were obtained 
from Applied Biosystems.  Table 2 contains the primers and their catalog 
numbers. Quantification was determined using the ΔΔCT method and normalized 
to the untreated sample. 
 
Table 2. Taqman Primers and Associated Catalog Numbers 
Primer Catalog Number 
Mouse Runx2 Mm00501580_m1 
Mouse Sp7 (Osx) Mm00504574_m1 
Mouse Bglap1 (Ocn) Mm03413826_m1 
Mouse Smad7 Mm00484742_m1 
Human IL-2 Hs00174114_m1 
Human TNFα Hs01113624_g1 
Human TNFSF11 (RANKL) Hs00243522_m1 
Human CD40LG Hs00163934_m1 
 
 
5.4 Western Blot Analysis 
Cells were lysed, on ice, for 20 min using lysis buffer containing 10mM Tris, pH 
7.6, 150mM NaCl, 2mM EDTA, 1% Triton, 0.1% sodium dodecyl sulfate (SDS), 
0.1 g deoxycholic acid, 1 tablet of protease inhibitor cocktail (Roche), 500 mM 
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sodium fluoride, 100 mM sodium pyrophosphate, and 400 mM β- 
glycerophosphate and centrifuged at 16,000 rpm for 10 min at 4 °C. Protein 
concentrations were determined using the BCA protein assay kit (Pierce). Equal 
amounts of protein (20 µg) were resolved by either 8% or 12% SDS 
polyacrylamide gel electrophoresis. Gels were transferred to Trans- Blot Transfer 
Medium Pure Nitrocellulose Membrane (Bio-Rad #162-0115) and probed with 
either Phospho-Smad 1/5/8 (Cell Signaling 9511S), Smad-1/5/8 (Santa Cruz SC 
6031R), TNFα (Cell Signaling 3707S) or β-actin (Cell Signaling 4970S) as 
primary antibodies overnight at 4 °C in 5% non-fat dry milk (Cell Signaling 
#9999). After washing with TBST (2% Tris, 3% NaCl and 0.5% Tween 20) 
membranes were probed with the corresponding secondary anti-rabbit HRP-
conjugated (Cell Signaling 7074S) for 1 hour at room temperature in 5% milk. 
Bands were visualized by chemiluminescence using Amersham ECL Western 
Blotting Detection Reagents (GE Healthcare RPN2106). To observe correlating 
amounts of total protein and phosphoprotein, the same blot was stripped for 30 
min at 65 °C in 62.5 mM Tris pH 6.8, 2%SDS and 0.6% β-mercaptoethanol. 
Stripped blots were washed for 30 min and then re-blocked before the primary 
antibody. Bands were analyzed for density with ImageJ and normalized to 
loading control Smad 1/5/8. Values represent fold change compared to untreated 
samples. 
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5.5 Alizarin Red Staining 
Cells were fixed with 2.5% glutaraldehyde after 21 days of stimulation and 
washed with PBS adjusted to a pH of 4.2. They were stained with 2% Alizarin 
Red S (Sigma-Aldrich A5533-25G) for 20 min at 37 °C. After being washed with 
PBS four images were captured for each well. 
 
5.6 T Cell Activation 
Primary CD4+ T cells, Jurkat and J-Lat cells were plate at 1x106 cells/3.8cm2.  If 
cells were being pre-treated with compounds, 1uM of JQ1 and/or rapamycin 
were added to the respective well for 1 hour and then cells were collected, spun 
down and washed prior to activation.  Primary CD4+ T cells were activated by 
adding antibodies against CD3 and CD28 (BD Biosciences 555336 and 555725 
respectively). Final concentrations for the antibodies were 0.1mg/ml for anti-CD3 
and 1mg/ml for CD28.  An hour after antibody addition, a secondary goat-anti-
mouse IgG (Life Technologies #A10535) was added at a final concentration of 
5mg/ml to cross-link the antibodies.  24 hours after secondary antibody addition, 
cells were collected for RNA, protein extraction or to be co-cultured with the 
osteoblasts.  Supernatants were also collected.  Jurkat and J-Lat cells were 
activated with 10ng/ml phorbol myristate acetate (PMA) for 24 hours after any 
pre-treatments, as described above.  Cells were collected for RNA, protein or co-
culturing and supernatants were collected for addition to osteoblasts.   
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5.7 JQ1 
JQ1 was given to us by Dr. Gerald Denis from Boston University School of 
Medicine, resuspended in DMSO.  10mM working solutions were made and 1uM 
was the final concentration added to the respective T cells.   
 
5.8 T Cell and Osteoblast Model System 
hFOB 1.19 cells were plated at 1.7x105 cells/3.8cm2 the same day the T cells 
were activated.  After the T cell activation, supernatants were collected and 
filtered through a 0.2um syringe filter and then added at a 1:1 ratio (500mL 
F12/DMEM and 500mL T cell supernatant).  The hFOBs were then placed into 
the differentiation temperature (390C) for 5 days.  When T cells were being co-
cultured with the osteoblasts, the T cells were collected and washed and 
resuspended in F12/DMEM prior to addition.  Once the T cells were added, 
hFOBs were placed into the differentiation temperature.  Two days after the 
addition of the T cells, they were removed and the hFOBs were washed and new 
media was added.  The hFOBs remained at the differentiation temperature for 3 
more days until the 5-day time point.  ALP staining, as previously described, was 
carried out after 5 days of differentiation. The method is represented in Figure 
21. 
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Figure 24 
 
Figure 24: Model of Osteoblast-T Cell Experiments. HIV- T cells: primary 
CD4+ T cells and Jurkat cells.  HIV+ T cells: J-Lat cells.   
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5.9 Statistics 
A student’s T-test was utilized in the StatPlus program with a two-tailed 
distribution set.  P values less than 0.05 were considered significant.  
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APPENDIX A: Relationship Between Poor Physical Function, Inflammatory 
Markers, and Comorbidities in HIV-Infected Women on Antiretroviral 
Therapy 
Parts of this appendix were previously published in Journal of Women’s Health, 
2014, 23:69-76. Baranoski, A., Harris, A., Michaels, D., Miciek, R., Storer, T., 
Sebastiani, P., Montano, M.  Copyright 2014. Mary Ann Libert Inc.  	  
A.1 Introduction 	  
For HIV-infected individuals receiving antiretroviral therapy (ART), HIV infection 
has been transformed from a deadly disease to a chronic condition. A growing 
number of individuals with HIV are now living into older age—about half of the 
1.5 million people with HIV in the United States will be aged 50 or older in 2015 
[293]. With the advent of ART, the incidence of previously common opportunistic 
infections has decreased [294]. However, HIV-infected individuals remain at 
higher risk for a variety of noninfectious comorbidities, including cardiovascular 
disease, lipid abnormalities, and diabetes [4, 295-299]. Multiple medical 
comorbidities are common in ART-treated individuals and older HIV-infected 
individuals are at increased risk for multiple comorbidities compared to the 
general population [4, 299, 300].   
 
HIV-infected individuals are also at increased risk for poor physical function, 
including the ‘‘frailty phenotype,’’ defined by the presence of three or more of the 
following: unintentional weight loss, self-reported exhaustion, weakness, slow 
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walking speed, and low physical activity [301]. HIV-infected individuals appear to 
have worse physical function compared to those without HIV [302-304]; however, 
poor physical function in HIV-infected individuals often appears related to low 
CD4 T-cell count or presence of other comorbidities, such as hypertension, 
diabetes, and chronic pulmonary disease [2, 302-307]. Worse physical function 
was associated with non-HIV-related comorbidities in studies conducted 
predominantly in HIV infected men [2, 304, 305, 307], although not in a study 
predominantly of women [308].  In contrast to one study in South Africa, in which 
frailty risk was decreased in individuals with higher body mass index (BMI) [308], 
poor physical function in HIV infected individuals in the United States has 
frequently been associated with obesity and truncal obesity [306, 307, 309]. HIV-
infected men may have a frailty prevalence comparable to uninfected men 10 
years older [303] and aerobic capacity more similar to HIV-uninfected men 20 
years older [310].  
 
The reasons behind the apparent decreased physical function in HIV-infected 
individuals are unclear. Several studies have reported associations between 
higher inflammatory biomarker levels, including interleukin-6 (IL-6), high-
sensitivity C-reactive protein (CRP), hyaluronic acid (HA), D-dimer, soluble CD14 
(sCD14), and soluble tumor necrosis factor receptor-1 (sTNFR1) and sTNFR2, 
and increased mortality in ART-treated individuals [177, 311-313].  Higher levels 
of inflammatory and coagulation biomarkers, such as IL-6, D-dimer, sCD14, and 
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CRP, are seen in HIV-infected individuals compared to HIV-uninfected controls, 
despite treatment with ART and adjustment for other comorbidities [314, 315]; 
however, one study suggested that these elevated biomarker levels in ART-
treated individuals were seen primarily in those with low CD4 counts or elevated 
HIV viral loads [315]. A recent study of HIV-infected individuals found that poor 
physical function was associated with immune activation and increased levels of 
IL-6 [316]. Higher levels of IL-6 and CRP are also associated with aging in the 
general population [317, 318] and have been associated with worse physical 
function in the elderly [319-323]. Worse scores on the Short Physical 
Performance Battery (SPPB), an assessment of physical function, have been 
associated with higher levels of IL-6 and CRP in individuals aged 55 years or 
older with chronic conditions, including chronic obstructive lung disease, 
congestive heart failure, high cardiovascular disease risk, and self-reported 
disability [324]. As HIV infection is associated with both increased inflammation 
and declines in physical function compared to the general population, it is 
possible that increased inflammation contributes to the declines in physical 
function seen in HIV-infected individuals despite apparent viral control with ART. 
The primary goal of this cross-sectional study was to assess the level of physical 
function of HIV-infected women on ART. Our goal was to describe differences in 
women with lower physical function compared to those with high function and to 
test the hypothesis that higher levels of inflammatory biomarkers are associated 
with poor physical function in this population. We chose to perform this study with 
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HIV-infected women because of the limited physical function research in this 
group and the increasing global burden of HIV infection in racial and ethnic 
minority women. 
 
A.2 Material and Methods 
 
Population enrolled 
This study was conducted at the Center for Infectious Diseases (CID) at Boston 
Medical Center in Boston, MA. The CID cares for approximately 1,400 HIV-
infected patients, including about 40% women, and is one of the largest HIV 
providers in New England. English-speaking HIV-infected women aged 40 and 
older on a stable ART regimen for at least 6 months with a most recent HIV viral 
load less than 1,000 copies/mL were eligible to participate. Women were 
recruited during medical appointments or through self-referral from study fliers in 
the clinic. After written informed consent was obtained, each woman completed a 
questionnaire that included information about demographic characteristics and 
medical history. ART regimen, nadir CD4 count, most recent CD4 and HIV viral 
load values, and date of HIV diagnosis were abstracted from the electronic 
medical record. We also collected information about hepatitis C, coronary artery 
disease, and comorbidities associated with cardiovascular disease, including 
hypertension, hyperlipidemia, and diabetes mellitus, as these conditions have 
been shown to be associated with increased risk of inflammation [315, 325-328]. 
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Medical comorbidities were defined by inclusion as an active problem in the 
electronic medical record. Serum was collected for biomarker quantification, and 
each woman underwent a physical- function assessment as described below. 
Body weight and height were recorded from the medical record and used to 
calculate BMI. The Boston University Medical Center Institutional Review Board 
approved this protocol. 
 
Physical-function testing 
Participants underwent a physical-function assessment consisting of the SPPB, 
which was conducted at the Boston Medical Center Laboratory for Exercise 
Physiology and Physical Performance. The SPPB was developed by the National 
Institute of Aging to assess physical function in individuals over 65 years of age 
and includes three measures: balance (defined by length of time able to stand 
with feet together, feet semitandem [big toe of one foot next to heel of the other], 
and tandem [heel to toe]), walking speed (best of two timed attempts at walking 
usual speed over a 4 meter distance), and chair stand (time to complete five 
transitions from sitting to standing without using arms) [329]. Each component of 
the SPPB is scored on a scale of 0 to 4, based on ability to complete the task 
and time required for completion, using the standardized scoring published 
previously for a maximum subscore of 4 for each component and a maximum 
overall score of 12. Although the SPPB was developed primarily for geriatric 
populations, we chose to use it as a function measure in our study because of 
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the increased prevalence of frailty and diminished physical function that occur at 
an earlier age in HIV-infected individuals. The physical-function assessment was 
scheduled on the same day as the questionnaire and blood draw when possible; 
however, the physical-function assessment was performed by different study 
staff in another building and thus could be scheduled for a separate visit if 
necessary. 
 
Inflammatory biomarkers 
A single blood draw was obtained from each subject for serum collection. As this 
was a cross-sectional study, we chose a variety of inflammatory and fibrotic 
markers implicated in prior studies of inflammation and HIV23–27 for possible 
inclusion in a future longitudinal study. The following tests were performed: 
enzyme-linked immunosorbent assays (ELISAs): IL-6 (R&D Systems D6050, 
Minneapolis, MN), sCD14 (a marker of monocyte activation) (R&D Systems 
DC140), soluble tumor necrosis factor receptor 1 (sTNFR1) (R&D Systems 
DRT100), transforming growth factor beta 1 (TGFb1) (R&D Systems DB100B), 
hyaluronic acid (a marker for tissue turnover and fibrosis) (Corgenix, Broomfield, 
CO), and lipopolysaccharide (LPS) (a marker of bacterial translocation) 
(Lonza QCL-1000 LALAssay 50-647U, Walkersville, MD). 
 
Statistical analysis 
We analyzed demographics, general medical and HIV-related information, SPPB 
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score, and inflammatory biomarker results, using descriptive statistics, including 
medians for continuous variables and proportions for categorical variables. 
We dichotomized our primary outcome, SPPB score, into low and high 
categories, using a cut-off score of 9 or lower to denote poor physical function, 
because scores in this range have been shown to be associated with increased 
risk of subsequent disability compared to scores of 10 to 12.43,44 Relationships 
between SPPB, inflammatory biomarkers, and potentially important covariates 
were assessed by Fisher’s exact test for categorical data and Wilcoxon rank sum 
test for continuous data. We created a medical-comorbidities variable that 
included hypertension, hepatitis C, hyperlipidemia, diabetes, and coronary artery 
disease. We also assessed SPPB as a continuous variable, using Spearman 
correlation testing. All analyses were conducted in SAS, Version 9.1 (Cary, ID). 
 
A.3 Results 
Seventy-two women were enrolled in the study between February and August 
2011, and 65 subjects (90%) completed the SPPB and are included in this 
analysis. The median age was 49 years (range 40–66 years), and 59 (91%) were 
racial and/or ethnic minorities, including 44 (68%) black and 11 (17%) 
Hispanicwomen (Table 3). Of 25 non-U.S.-born women, the majority were born in 
Haiti or on the African continent. The median BMI was 28.0 (IQR 24.2–33.7), and 
26 subjects (40%) were obese (BMI ‡ 30 kg/m2). Medical comorbidities included 
hypertension (49%), hepatitis C (28%), hyperlipidemia (28%), diabetes (25%), 
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and coronary artery disease (5%). The seven excluded subjects did not attend 
SPPB testing. No subjects were excluded for safety reasons or because they 
were unable to complete SPPB testing. Excluded subjects were more likely to 
report active drug use (43% vs. 9% of subjects who underwent SPPB testing); 
otherwise, there were no significant differences in demographic or medical 
variables between subjects included in this analysis and excluded individuals. 
HIV history is reported in Table 3. Although 49% of women with a known nadir 
CD4 count had a nadir less than 200 CD4 cells/mm3, 43 subjects (66%) had a 
current CD4 count of ‡ 500 cells mm3, and 58 (89%) had a current HIV viral load 
£ 75 copies/mL. The levels of inflammatory biomarkers for the cohort are shown 
in Table 4. The median SPPB score was 11 out of 12 (range 6–12). Thirteen of 
65 subjects (20%) had an SPPB score of 9 or lower (Table 5). There were 
greater differences in walking speed and chair-stand time (a surrogate for leg 
power) between the low and high-scoring SPPB groups compared to balance 
score. Women with a low SPPB score were more likely to be current cigarette 
smokers and had more medical comorbidities, including hypertension, hepatitis 
C, hyperlipidemia, diabetes, and coronary artery disease (Table 5). Women in 
the low-SPPB group tended to be older (p = 0.06) and be more likely to have 
diabetes (p = 0.07). There were no apparent differences between women in the 
low- and high-SPPB groups in terms of current or nadir CD4 count or current viral 
load. Women in the low-SPPB group had higher IL-6 levels and a trend toward 
higher sTNFR1 levels (Table 5). More than 50% of our subjects had IL-6 levels 
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below the limit of detection; when IL-6 was analyzed as a dichotomous variable, 
9 subjects (69%) in the low-SPPB group had a detectable IL-6 level compared to 
19 subjects (39%) in the higher-SPPB group ( p = 0.06) (results not shown). In 
Spearman correlation testing, SPPB score was inversely associated with 
sTNFR1 (correlation coefficient - 0.29, p = 0.02). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   152 
Table 3: Baseline Demographic and Medical Information (N=65) 
 
Data are presented as number (percent) or median (interquartile range) 
Characteristic Result
Demographic Information
Age (years) 49 (45-55)
Race/Ethnicity
White, not Hispanic 6 (9)
Black, not Hispanic 44 (68)
Hispanic 11 (17)
Other or mixed race 4 (6)
Born in United States 40 (62)
Married or living with partner 20 (31)
High school graduate or higher education 38 (58)
Unemployed 41 (63)
Illicit drug juse (n=64)
Current 6 (9)
Former 25 (39)
Smoking Status
Current 22 (34)
Former 14 (22)
General Medical Information
BMI Category
Less than 25 18 (28)
25 to less than 30 21 (32)
30 to less than 35 17 (26)
Greater than 35 9 (14)
Hypertension 32 (49)
Hepatitis C infection 18 (28)
Hyperlipidemia 18 (28)
Diabetes 16 (25)
Coronary artery disease 3 (5)
Number of comorbid medical conditions
0 16 (25)
1 26 (40
2 or more 23 (35)
HIV History
Years since HIV diagnosis 13 (8-16)
Nadir CD4 T-cell count (cells/mm3) (n=61) 202 (96-269)
Current CDR T-cell count (cells/mm3) 675 (436-828)
Current HIV viral load greater than 75 copies/mL 58 (89)
	  	   153 
Table 4 
  
Table 4: Inflammatory Biomarker Levels for the Entire Cohort 
sTNFR1: soluble tumor necrosis factor receptor-1, sCD14: soluble CD14, 
TGFβ1: transforming growth factor beta 1, IL-6: interleukin-6, HA: hyaluronic 
acid, LPS: lipopolysaccharide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory Biomarker Median (Interquartile Range)
sTNFR1 (ng/mL) (n=62) 1.7 (1.3-2.0)
sCD14 (µg/mL) (n=62) 1.7 (1.6-2.2)
TGFβ1 (ng/mL) (n=59) 28.6 (17.5-43.3)
IL-6 (pg/mL) (n=62) 0 (0-2)
HA (ng/ml) (n=61) 0.6 (0-2.9)
LPS (endotoxin unit) (n=61) 0.8 (0.4-1.2)
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Table 5: Factors Associated with Poor Short Physical Performance Battery Score 
 
Results presented as number (percent) or (interquartile range) 
 
 
 
 
Characteristic SPPB <9 (n=13) SPPB >9 (n=52) p-value
Demographic Variables
Age (years) 55 (48-56) 48#(44%54) 0.06
Race/Ethnicity
Black 9 (69) 35#(67) 1
White 1 (8) 5#(10)
Hispanic 2 (15) 9#(17)
Other 1 (8) 3#(6)
Current Cigarette Smoker 8 (62) 14#(27) 0.03
Current Illicit Drug Use 0 6#(12) 0.03
General Medical Variables
Body Mass Index 30.5 (25.6-34.5) 27.9#(23.8%32.4) 0.38
Hypertension 9 (69) 23#(44) 0.13
Hepatitis C Infection 6 (46) 12#(23) 0.16
Hyperlipidemia 4 (31) 14#(27) 0.74
Diabetes 6 (46) 10#(19) 0.07
Number of Comorbid Medical Conditions
0 1 (8) 15#(29) 0.01
1-2 7 (54) 33#(63)
3 or more 5 (38) 4#(8)
HIV Variables
Nadir CD4 T-cell count (cells/mm3) (n=61) 202 (70-223) 200.5#(125%269.5) 0.51
Current CDR T-cell count (cells/mm3) 595 (471-826) 678.5#(427%831.5) 0.95
Current HIV viral load greater than 75 copies/mL 10 (77) 48#(92) 0.14
Component Scores of SPPB
Balance 4 (3-4) 4#(4%4) 0.054
Walking Speed 3 (3-3) 4#(4%4) <0.0001
Char Stand Time 2 (1-3) 4#(3.5%4) <0.0001
Inflammatory Variables
sTNFR1 2.0 (1.7-2.5) 1.6#(1.3%1.8) 0.09
sCD14 2.0 (1.5-2.2) 1.7#(1.6%2.0) 0.84
TGFβ1 25.4 (19.1-47.8) 32.2#(17.5%40.7) 0.98
IL-6 1 (0-3) 0#(0%1) 0.048
HA 1.5 (0-12.6) 0.2#(0%2.6) 0.17
LPS 0.8 (0.2-1.0) 0.8#(0.4%1.2) 0.54
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A.4 Discussion, Future Directions and Limitations 
We found that 20% of HIV-infected women in this study had an SPPB score of 9 
or lower, despite the fact that ART was effective in improving markers of HIV 
infection in the majority of subjects. Given the levels of immune reconstitution 
and viral suppression in these subjects, the SPPB scores were still low in 20% of 
our relatively young subjects on a test designed to assess decreased physical 
function in elderly individuals aged 65 years and older. It is concerning that one-
fifth of our sample of relatively young participants with well-controlled HIV scored 
in a SPPB range associated with increased risk of developing disabilities [329, 
330]. For comparison, in a study of men and women aged 65 years and older in 
the general population, 26% scored 9 or lower on the SPPB [331]. Over half 
(53%) of community-dwelling adults aged 71 or older had an SPPB score of 9 or 
lower at baseline, and individuals with a baseline SPPB of 7 to 9 (the scores for 
the majority of our subjects with poor physical function) had 1.6 times the risk of 
disability in activities of daily living by 4 years compared to individuals with an 
SPPB of 10 to 12 [332]. In an additional analysis, the risk of subsequent disability 
for those with poor physical function was 1.8 to 2.1 times higher at 1 year and 1.5 
to 1.9 times higher at 4 years after follow-up for elderly individuals with a baseline 
SPPB score of 7 to 9. The authors of that study projected from their results that 
about 10% of women aged 65 to 69 years with an SPPB score of 9 or lower 
would be disabled by one 1 year, increasing to 39% of women aged 85 to 89 
years with an SPPB score of 9 or lower [330]. This portends that younger HIV-
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infected women with low SPPB scores may have higher utilization of healthcare 
resources and risk of disability in the future. As the number of HIV-infected 
individuals living into older age will only continue to increase, additional research 
on physical function and disability in this population is needed. 
A recently published study that assessed physical function in HIV-infected 
individuals aged 45 to 65 years on ART for at least 6 months found that, whereas 
a similar proportion of subjects had poor function, as defined by an SPPB score 
less than 9 in that study (7% in their population vs. 9% in our population), 
significantly more subjects in that cohort had no physical-function deficits 
compared to our cohort (62% vs. 45%, p=0.01). Although that study population is 
similar to our cohort in terms of age, median current CD4 >500 cells/mm3, and 
proportion of current smokers, that cohort consisted primarily of Caucasian (74%) 
men (85%) who have sex with men as their HIV risk factor (65%), which is starkly 
different compared to our study population. Women in the general population, as 
well as those with HIV infection, appear to be at increased risk for poor physical 
function  
[301, 307, 308, 333]; however, the population in the study by Erlandson et al. and 
our cohort are too different to directly compare whether the difference in SPPB 
performance between the two groups is related to gender. To our knowledge, 
only two previous studies have assessed physical function and HIV infection in 
predominantly female populations. Terzian et al. found that the overall frailty 
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prevalence in a younger cohort of HIV-infected women (median age 41 years, 
IQR 36–47 years) was less than 10%, which was similar to an HIV-uninfected 
comparison group [302].  In a study of South Africans consisting of 74% women, 
HIV-infected individuals were at increased risk for frailty compared to HIV-
uninfected subjects; however, less than 20% of that cohort was aged 50 or older, 
and increased risk of frailty was significantly associated with increasing age in 
women but not men [308].  As the subjects in that study were relatively young, 
further study is needed to see how HIV infection impacts physical function as 
women age. 
Forty percent of subjects in our study had one medical comorbidity (including 
hypertension, hepatitis C, hyperlipidemia, diabetes, and coronary artery disease), 
and 35% had two or more medical comorbidities. Women with greater numbers 
of medical comorbidities were more likely to have poor SPPB performance. This 
raises the question whether there is truly a connection between poor physical 
function and HIV infection or whether poor physical function in HIV-infected 
individuals is due primarily to comorbidities, such as hypertension and diabetes. 
A greater proportion of women in the low-SPPB-score group had diabetes, 
hypertension, and hepatitis C. However, these differences were not statistically 
significant when compared to women with an SPPB score greater than 9. Since 
this study was not powered to assess differences in prevalence of individual 
comorbid conditions, these findings must be replicated in larger studies. Because 
we were interested in the link between inflammatory biomarkers and poor 
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physical function, we chose to focus this study on cardiovascular comorbidities 
and hepatitis C, which have previously been shown to be associated with 
increased inflammation [315, 325, 326].  The high frequency of comorbidities in 
our cohort composed of 91% racial and/or ethnic minority women appears 
consistent with what is observed in minority women of a similar age in the 
general U.S. population with regard to high BMI [334], hypertension [335], 
hyperlipidemia, and diabetes [336] and the consequent increased risk for obesity 
and related complications [334]. The association between non-HIV-related 
comorbidities and poor physical function seen in our study is in line with prior 
studies focused largely on men.  Women with poor SPPB performance were also 
more likely to be current smokers. Cigarette smoking has been associated with 
worse physical function in some studies of HIV-infected and uninfected 
individuals but not others; however, it is unclear from our analysis whether 
cigarette smoking is a risk factor for other medical comorbidities or is directly 
associated with poor physical function. 
Although lower CD4 count has been associated with increased risk of frailty in 
multiple studies, current or nadir CD4 count was not statistically different 
between the low- and high-SPPB groups. A smaller proportion of women in the 
low-SPPB-score group had a viral load ≤75 copies/mL; however, this study was 
underpowered to assess the relationship between low SPPB score and CD4 
count or HIV viral load. We did not collect information on prior opportunistic 
infection history or AIDS-defining events other than nadir CD4 count. In order to 
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control for higher levels of inflammation due to untreated HIV, all participants in 
this study were on stable ART for at least 6 months. Two-thirds had a CD4 count 
≥500 cells/mm3, and 89% had a viral load ≤75 copies/mL; therefore, our 
population likely has better physical function compared to the group of HIV-
infected women over age 40 as a whole. In addition, only one subject who 
completed the physical-function assessment was older than 65. Thus, the burden 
of poor physical function in HIV-infected individuals is likely to increase as this 
population continues to age. 
As seen in studies of the elderly and individuals with other chronic 
conditions,[337] higher levels of IL-6 and sTNFR1 were associated with worse 
physical-function performance in HIV-infected women in our study. It is unclear 
from this cross-sectional study whether these inflammatory-profile differences are 
truly related to worse physical-function performance or simply a marker of the 
increased burden of comorbidities seen in the low-SPPB-score group. One study 
has looked at the association between inflammation and immune activation and 
functional impairment in HIV-infected individuals and found that after adjustment 
for CD4 count, tobacco use, and hepatitis B and C, poor physical function was 
associated with low CD4 count, high CD8 count, low CD4:CD8 ratio, immune 
activation as evidenced by percent of CD38/HLA-DR/CD8 T-cells, and increased 
level of IL-6 but not markers of microbial translocation (including LPS) or immune 
senescence. TNF-alpha and sCD14 were associated with increased risk of poor 
function in unadjusted, but not adjusted, analysis in that study, which was 
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conducted in a predominantly male and Caucasian population [316].  As both 
elderly and HIV-infected individuals have increased levels of inflammatory 
biomarkers, it makes sense that higher inflammatory profile could be a 
contributor to the diminished physical function seen in those with HIV. One study 
showed that elevated inflammatory biomarkers in ART-treated individuals were 
associated with an HIV viral load ≥500 copies/mL or CD4 count <200 cells/mm, 
however, almost none of our subjects met these criteria. 
Strengths of our study included that it was conducted in a population of 
predominantly minority women, with a racial and ethnic breakdown 
representative of HIV-infected women in the United States as a whole. To our 
knowledge, only one other study of physical function has focused solely on 
women with HIV. In addition, the physical-function assessment was conducted by 
trained exercise physiologists under standardized conditions. 
There are some limitations to this study. Although 20% of subjects performed 
poorly on the SPPB, the SPPB was designed for elderly populations. The median 
SPPB score of 11 out of 12 in our study suggests that there is likely a ceiling 
effect to the SPPB in that some of our subjects who performed well on the SPPB 
may have physical-function limitations that would be apparent on a more rigorous 
test of physical function. The benefit of using the SPPB, however, is that it can 
easily and quickly be conducted in a clinical setting with minimal training for staff. 
Although we felt that it was important to limit the study to women with well-
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controlled HIV in order to limit variation in inflammation due to untreated HIV 
infection, the fact that all subjects were on stable ART and that the majority had a 
high CD4 T-cell count and HIV viral load of 75 copies/mL or lower means that our 
findings are likely not generalizable to the entire population of HIV-infected 
women over age 40. In addition, our study population was relatively young, with 
only five women aged 60 years or older; however, the age distribution of our 
cohort is representative of English-speaking women over 40 years of age on ART 
in our large female patient population. Further research will need to be done to 
assess the rate of decline in physical function as the population of HIV-infected 
women grows older. Finally, although we were able to compare the prevalence of 
poor SPPB score in our population with studies of older individuals in the general 
population and a largely male HIV-infected cohort, we were unable to include an 
age- and race/ethnicity-matched HIV seronegative comparison group, and an 
appropriate HIV-negative comparison group will be important for future research. 
 
A.5 Conclusions 
Our cross-sectional study identified 20% of relatively young HIV-infected women 
with poor physical function despite treatment with ART and good levels of 
immune reconstitution and viral suppression. Women with inflammatory 
comorbidities and higher systemic inflammation were at increased risk for poor 
physical function. A better understanding of the relationship between chronic 
inflammation and poor physical function in HIV-infected individuals will be 
	  	   162 
necessary in order to decrease risk for disability at a younger age in this 
population. These issues warrant exploration in a larger longitudinal study. 
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